Are you over 18 and want to see adult content?
More Annotations
![A complete backup of biancahester.net](https://www.archivebay.com/archive5/images/0c0ce046-9ecd-432b-83d8-c47a577af8aa.png)
A complete backup of biancahester.net
Are you over 18 and want to see adult content?
![A complete backup of beverlyhillshotel.com](https://www.archivebay.com/archive5/images/bb113a9a-df1e-425f-909e-54b28582561c.png)
A complete backup of beverlyhillshotel.com
Are you over 18 and want to see adult content?
![A complete backup of chillingwithlucas.com](https://www.archivebay.com/archive5/images/66a46c5c-a150-4bfc-b219-9139a4efe469.png)
A complete backup of chillingwithlucas.com
Are you over 18 and want to see adult content?
Favourite Annotations
![Dedicated and Cloud Servers, Colocation, PaaS, IaaS | Servers Australia](https://www.archivebay.com/archive/b5f3c75c-a4b6-45e1-bdbe-24184cd7d48f.png)
Dedicated and Cloud Servers, Colocation, PaaS, IaaS | Servers Australia
Are you over 18 and want to see adult content?
![cionscollector – شرح مواقع الربح من الانترنت الاكثر مصداقية](https://www.archivebay.com/archive/4bbfe8a9-90b7-4117-a117-79cec400a6bc.png)
cionscollector – شرح مواقع الربح من الانترنت الاكثر مصداقية
Are you over 18 and want to see adult content?
![The Frugal Scribbler | Just another frugal website](https://www.archivebay.com/archive/b486ddfe-8ec0-4cf3-82eb-324ff156bb25.png)
The Frugal Scribbler | Just another frugal website
Are you over 18 and want to see adult content?
![QMCSPORTS - Tin tức thể thao bóng đá trực tuyến - Blog](https://www.archivebay.com/archive/de78e35c-c0a7-442a-a83f-04cb95b80f83.png)
QMCSPORTS - Tin tức thể thao bóng đá trực tuyến - Blog
Are you over 18 and want to see adult content?
![YoYoJogo - Free games, online games and new games](https://www.archivebay.com/archive/5aef4788-e5f6-4cd0-8a7a-5bf6d8ece230.png)
YoYoJogo - Free games, online games and new games
Are you over 18 and want to see adult content?
![My Wedding Reception Ideas](https://www.archivebay.com/archive/cbbf7aa2-edb1-402f-8bdc-fe539d3c6e8f.png)
My Wedding Reception Ideas
Are you over 18 and want to see adult content?
![A complete backup of deinemeinungzaehlt.com](https://www.archivebay.com/archive/15d8a6c8-0f58-40be-aa9d-159a4af2631a.png)
A complete backup of deinemeinungzaehlt.com
Are you over 18 and want to see adult content?
![Portada - Izquierda Web - Noticias de los trabajadores, las mujeres y la juventud](https://www.archivebay.com/archive/9e96ffe7-4561-4ea7-9f25-a7b60ea64fc4.png)
Portada - Izquierda Web - Noticias de los trabajadores, las mujeres y la juventud
Are you over 18 and want to see adult content?
Text
in
ASCO 2020: TALAPRO-2: A PLACEBO-CONTROLLED PHASE III STUDY ASCO 2020 TALAPRO-2 trial patients with metastatic castration-resistant prostate cancer, TALAPRO-2 trial PARP inhibitor, TALAPRO-2 trial efficacy and safety, TALAPRO-2 trial patient-reportedoutcomes
ASCO GU 2021: NIVOLUMAB PLUS IPILIMUMAB IN PATIENTS WITH Published 13 February 2021 (UroToday.com) The long-term efficacy and tolerability of nivolumab 3 mg/kg plus ipilimumab 1 mg/kg Q3W × 4 doses followed by nivolumab 3 mg/kg Q2W for previously untreated advanced renal cell carcinoma (RCC) demonstrated in the registrational CheckMate 214 clinical trial 1 was based on patients with a predominantly clear cell component. ASCO 2020: KEYNOTE-426: PEMBROLIZUMAB PLUS AXITINIB VERSUS (UroToday.com) KEYNOTE-426 was a large phase III clinical trial that randomly assigned 861 patients with clear cell (renal cell carcinoma) RCC to either pembrolizumab + axitinib (5 mg BID) or sunitinib (50 mg daily x 4 weeks, 6-week cycle). This data, initially presented at GU ASCO 2019, showed that combination pembrolizumab plus axitinib significantly improved overall survival at 1 year (90% COMPARISON OF MAJOR COMPLICATIONS AT 30 AND 90 DAYS October 20, 2020 Radical cystectomy is associated with some of the highest rates of morbidity and mortality in the field of urologic surgery. Despite this burden, there remains a lack of consensus as to when it is most useful to assess complications across the post-surgical recovery period. FIVE-YEAR REZŪM OUTCOMES DEMONSTRATE EFFECTIVE LONG-TERM Five-Year Rezūm Outcomes Demonstrate Effective Long-Term BPH Treatment. April 8, 2020. New clinical study results demonstrate Rezūm is proven to give men suffering from BPH sustained symptom relief and quality of life improvements for 5 years. San Francisco, CA (UroToday.com) -- Results of a five-year clinical trial confirming thelong-term
THE ROLE OF PSA MONITORING AFTER HOLMIUM LASER ENUCLEATION 55 patients underwent "for cause" transrectal ultrasound prostate biopsy following HoLEP. Cancer was identified in over 90% of those biopsied. Men with PSA above 1 at time of biopsy had a 94% probability of cancer detection and 80% risk of clinically significant disease. PSAD above 0.1 was associated with a 95% risk of cancer and 88% riskof
UROTODAY - THE GLOBAL ONLINE COMMUNITY OF UROLOGISTSCENTERS OF EXCELLENCEVIDEOSJOURNALSCLINICAL TRIALSCONFERENCE COVERAGECALENDAR June 26, 2020, marked the 20 th anniversary of the publication of the first working draft from the Human Genome Project. At a special White House event to commemorate the results of this 10-year public effort (it was really more like 50 years since the discovery of DNA, but I digress), then-President Bill Clinton called the project “the most wondrous map ever created by humankind”, and ASCO GU 2021: THE ORAL HIF-2 Α INHIBITOR MK-6482 IN ASCO GU 2021 Genitourinary Cancers Symposium, The Oral HIF-2 α Inhibitor MK-6482 in Patients with Advanced Clear Cell Renal Cell Carcinoma (RCC): Updated Follow-up of a Phase I/II Study ASCO GU 2021: PRIMARY RESULTS OF EV-301: A PHASE III TRIAL ASCO GU 2021 Genitourinary Cancers Symposium Primary Results of EV-301: A Phase III Trial of Enfortumab Vedotin Versus Chemotherapy in Patients with Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma, EV-301, Enfortumab Vedotin GSRGT 2020: CLINICAL TRIALS CORNER: TIGER TRIAL GSRGT 2020: Clinical Trials Corner: TIGER Trial. (Urotoday.com) The newly formed Global Society of Rare Genitourinary Tumors (GSRGT) held its inaugural meeting, focusing on penile and testicular cancer. The session held Saturday, December 12 th focused on testis cancer. In this session, the organizers convened a “Clinical Trials Corner”in
ASCO 2020: TALAPRO-2: A PLACEBO-CONTROLLED PHASE III STUDY ASCO 2020 TALAPRO-2 trial patients with metastatic castration-resistant prostate cancer, TALAPRO-2 trial PARP inhibitor, TALAPRO-2 trial efficacy and safety, TALAPRO-2 trial patient-reportedoutcomes
ASCO GU 2021: NIVOLUMAB PLUS IPILIMUMAB IN PATIENTS WITH Published 13 February 2021 (UroToday.com) The long-term efficacy and tolerability of nivolumab 3 mg/kg plus ipilimumab 1 mg/kg Q3W × 4 doses followed by nivolumab 3 mg/kg Q2W for previously untreated advanced renal cell carcinoma (RCC) demonstrated in the registrational CheckMate 214 clinical trial 1 was based on patients with a predominantly clear cell component. ASCO 2020: KEYNOTE-426: PEMBROLIZUMAB PLUS AXITINIB VERSUS (UroToday.com) KEYNOTE-426 was a large phase III clinical trial that randomly assigned 861 patients with clear cell (renal cell carcinoma) RCC to either pembrolizumab + axitinib (5 mg BID) or sunitinib (50 mg daily x 4 weeks, 6-week cycle). This data, initially presented at GU ASCO 2019, showed that combination pembrolizumab plus axitinib significantly improved overall survival at 1 year (90% COMPARISON OF MAJOR COMPLICATIONS AT 30 AND 90 DAYS October 20, 2020 Radical cystectomy is associated with some of the highest rates of morbidity and mortality in the field of urologic surgery. Despite this burden, there remains a lack of consensus as to when it is most useful to assess complications across the post-surgical recovery period. FIVE-YEAR REZŪM OUTCOMES DEMONSTRATE EFFECTIVE LONG-TERM Five-Year Rezūm Outcomes Demonstrate Effective Long-Term BPH Treatment. April 8, 2020. New clinical study results demonstrate Rezūm is proven to give men suffering from BPH sustained symptom relief and quality of life improvements for 5 years. San Francisco, CA (UroToday.com) -- Results of a five-year clinical trial confirming thelong-term
THE ROLE OF PSA MONITORING AFTER HOLMIUM LASER ENUCLEATION 55 patients underwent "for cause" transrectal ultrasound prostate biopsy following HoLEP. Cancer was identified in over 90% of those biopsied. Men with PSA above 1 at time of biopsy had a 94% probability of cancer detection and 80% risk of clinically significant disease. PSAD above 0.1 was associated with a 95% risk of cancer and 88% riskof
UROTODAY - THE GLOBAL ONLINE COMMUNITY OF UROLOGISTS Presented by Michael J. Morris, MD. The case presented was that of a 54-year-old man with an extensive family history of cancer. His mother died from ovarian cancer, his father had prostate cancer and died of colon cancer, his brother developed kidney and prostate SNMMI 2021 ANNUAL MEETING 1 day ago · Were you unable to attend SNMMI 2021 Annual Meeting? Get all of the groundbreaking research, new guidelines, and the latest advances in urologic medicine you missed.PROSTATE CANCER
Clinical Outcomes and Racial Disparities in Metastatic Hormone-Sensitive Prostate Cancer in the Era of Novel Treatment Options. June 9, 2021 Variation in the Use of Active Surveillance for Low-Risk Prostate Cancer Across US Census Regions. June ESMO VIRTUAL CONGRESS 2020: NIVOLUMAB + IPILIMUMAB VS ESMO 2020 CheckMate214 trial, comparing nivolumab and ipilumumab to sunitinib, patients with advanced clear cell renal cell carcinoma, JAVELIN Renal 101 trial, KEYNOTE-426 trial.PROSTATE CANCER
How Has Prostate Cancer Radiotherapy Changed in Italy between 2004 and 2011? An Analysis of the National Patterns-Of-Practice (POP) Database by the Uro-Oncology Study Group of the Italian Society of Radiotherapy and Clinical Oncology (AIRO). June 4, 2021 Response and Toxicity to the Second Course ofPROSTATE CANCER
UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology. - Results from #20URINARY BYPASSING
In this video from Diane Newman, she provides an expert's perspective on a common problem faced by individuals with transurethral indwelling catheters, or a Foley catheter — urinary bypassing, in which urine leaks around the catheter. She first addresses why this may occur, citing possible catheter blockages, an incorrectly sized catheter, a latex allergy, or bladder overactivity. ShePROSTATE CANCER
Extent of High-Grade Prostatic Adenocarcinoma in Multiparametric Magnetic Resonance Imaging-Targeted Biopsy Enhances Prediction of Pathologic Stage. May 24, 2021 Characterizing Prostate-Specific Antigen Levels at Death in Patients with Metastatic Castration-Resistant Prostate Cancer: Are WePROSTATE CANCER
Response and Toxicity to the Second Course of 3 Cycles of 177Lu-PSMA Therapy Every 4 Weeks in Patients with Metastatic Castration-Resistant Prostate Cancer. June 4, 2021 Association of Molecular Subtypes With Differential Outcome to Apalutamide Treatment in Nonmetastatic Castration-ResistantPROSTATE CANCER
Cost-effectiveness of multiparametric magnetic resonance imaging and MRI-guided biopsy in a population-based prostate cancer screening setting using a micro-simulation model. May 19, 2021 An integrated multicomponent care model for men affected by prostate cancer: A UROTODAY - THE GLOBAL ONLINE COMMUNITY OF UROLOGISTSCENTERS OF EXCELLENCEVIDEOSJOURNALSCLINICAL TRIALSCONFERENCE COVERAGECALENDAR June 26, 2020, marked the 20 th anniversary of the publication of the first working draft from the Human Genome Project. At a special White House event to commemorate the results of this 10-year public effort (it was really more like 50 years since the discovery of DNA, but I digress), then-President Bill Clinton called the project “the most wondrous map ever created by humankind”, and ASCO GU 2021: PRIMARY RESULTS OF EV-301: A PHASE III TRIAL ASCO GU 2021 Genitourinary Cancers Symposium Primary Results of EV-301: A Phase III Trial of Enfortumab Vedotin Versus Chemotherapy in Patients with Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma, EV-301, Enfortumab Vedotin ASCO GU 2021: NIVOLUMAB PLUS IPILIMUMAB IN PATIENTS WITH Published 13 February 2021 (UroToday.com) The long-term efficacy and tolerability of nivolumab 3 mg/kg plus ipilimumab 1 mg/kg Q3W × 4 doses followed by nivolumab 3 mg/kg Q2W for previously untreated advanced renal cell carcinoma (RCC) demonstrated in the registrational CheckMate 214 clinical trial 1 was based on patients with a predominantly clear cell component. ASCO GU 2021: THE ORAL HIF-2 Α INHIBITOR MK-6482 IN ASCO GU 2021 Genitourinary Cancers Symposium, The Oral HIF-2 α Inhibitor MK-6482 in Patients with Advanced Clear Cell Renal Cell Carcinoma (RCC): Updated Follow-up of a Phase I/II Study ASCO GU 2021: DOSE-INTENSIFIED VERSUS CONVENTIONAL DOSE ASCO GU 2021 Genitourinary Cancers Symposium Dose-Intensified Versus Conventional Dose-Salvage Radiotherapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: Six-Year Outcomes of the SAKK 09/10 Randomized Phase III Trial, tolerability of conventional vs. dose-intensified salvage radiation therapy, ASCO GU 2021: ENFORTUMAB VEDOTIN IN PREVIOUSLY TREATED Published 17 February 2021 (UroToday.com) In this presentation, Arlene O. Siefker-Radtke, MD from the University of Texas MD Anderson Cancer Center provided a discussion on two presentations on Enfortumab Vedotin (EV) in previously treated urothelial cancer. COMPARISON OF MAJOR COMPLICATIONS AT 30 AND 90 DAYS October 20, 2020 Radical cystectomy is associated with some of the highest rates of morbidity and mortality in the field of urologic surgery. Despite this burden, there remains a lack of consensus as to when it is most useful to assess complications across the post-surgical recovery period.COMPLICATIONS
Complications can include urethral/scrotal events can include bleeding, urethritis, stricture, the creation of a false passage, and epididymitis. Bladder-related events can cause UTIs, bleeding, and stones. The most frequent complication of IC is a catheter-associated urinary tract infection (CAUTI). It THE ROLE OF PSA MONITORING AFTER HOLMIUM LASER ENUCLEATION 55 patients underwent "for cause" transrectal ultrasound prostate biopsy following HoLEP. Cancer was identified in over 90% of those biopsied. Men with PSA above 1 at time of biopsy had a 94% probability of cancer detection and 80% risk of clinically significant disease. PSAD above 0.1 was associated with a 95% risk of cancer and 88% riskof
INDICATIONS FOR AN INDWELLING (FOLEY) CATHETER 2013 Written by Diane K. Newman © 2013 Diane K. Newman and UroToday, Inc. Indications for an Indwelling (Foley) Catheter Short-term for acuteurinary retention
UROTODAY - THE GLOBAL ONLINE COMMUNITY OF UROLOGISTSCENTERS OF EXCELLENCEVIDEOSJOURNALSCLINICAL TRIALSCONFERENCE COVERAGECALENDAR June 26, 2020, marked the 20 th anniversary of the publication of the first working draft from the Human Genome Project. At a special White House event to commemorate the results of this 10-year public effort (it was really more like 50 years since the discovery of DNA, but I digress), then-President Bill Clinton called the project “the most wondrous map ever created by humankind”, and ASCO GU 2021: PRIMARY RESULTS OF EV-301: A PHASE III TRIAL ASCO GU 2021 Genitourinary Cancers Symposium Primary Results of EV-301: A Phase III Trial of Enfortumab Vedotin Versus Chemotherapy in Patients with Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma, EV-301, Enfortumab Vedotin ASCO GU 2021: NIVOLUMAB PLUS IPILIMUMAB IN PATIENTS WITH Published 13 February 2021 (UroToday.com) The long-term efficacy and tolerability of nivolumab 3 mg/kg plus ipilimumab 1 mg/kg Q3W × 4 doses followed by nivolumab 3 mg/kg Q2W for previously untreated advanced renal cell carcinoma (RCC) demonstrated in the registrational CheckMate 214 clinical trial 1 was based on patients with a predominantly clear cell component. ASCO GU 2021: THE ORAL HIF-2 Α INHIBITOR MK-6482 IN ASCO GU 2021 Genitourinary Cancers Symposium, The Oral HIF-2 α Inhibitor MK-6482 in Patients with Advanced Clear Cell Renal Cell Carcinoma (RCC): Updated Follow-up of a Phase I/II Study ASCO GU 2021: DOSE-INTENSIFIED VERSUS CONVENTIONAL DOSE ASCO GU 2021 Genitourinary Cancers Symposium Dose-Intensified Versus Conventional Dose-Salvage Radiotherapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: Six-Year Outcomes of the SAKK 09/10 Randomized Phase III Trial, tolerability of conventional vs. dose-intensified salvage radiation therapy, ASCO GU 2021: ENFORTUMAB VEDOTIN IN PREVIOUSLY TREATED Published 17 February 2021 (UroToday.com) In this presentation, Arlene O. Siefker-Radtke, MD from the University of Texas MD Anderson Cancer Center provided a discussion on two presentations on Enfortumab Vedotin (EV) in previously treated urothelial cancer. COMPARISON OF MAJOR COMPLICATIONS AT 30 AND 90 DAYS October 20, 2020 Radical cystectomy is associated with some of the highest rates of morbidity and mortality in the field of urologic surgery. Despite this burden, there remains a lack of consensus as to when it is most useful to assess complications across the post-surgical recovery period.COMPLICATIONS
Complications can include urethral/scrotal events can include bleeding, urethritis, stricture, the creation of a false passage, and epididymitis. Bladder-related events can cause UTIs, bleeding, and stones. The most frequent complication of IC is a catheter-associated urinary tract infection (CAUTI). It THE ROLE OF PSA MONITORING AFTER HOLMIUM LASER ENUCLEATION 55 patients underwent "for cause" transrectal ultrasound prostate biopsy following HoLEP. Cancer was identified in over 90% of those biopsied. Men with PSA above 1 at time of biopsy had a 94% probability of cancer detection and 80% risk of clinically significant disease. PSAD above 0.1 was associated with a 95% risk of cancer and 88% riskof
INDICATIONS FOR AN INDWELLING (FOLEY) CATHETER 2013 Written by Diane K. Newman © 2013 Diane K. Newman and UroToday, Inc. Indications for an Indwelling (Foley) Catheter Short-term for acuteurinary retention
PROSTATE CANCER
Clinical Outcomes and Racial Disparities in Metastatic Hormone-Sensitive Prostate Cancer in the Era of Novel Treatment Options. June 9, 2021 Variation in the Use of Active Surveillance for Low-Risk Prostate Cancer Across US Census Regions. June ASCO GU 2021: DOSE-INTENSIFIED VERSUS CONVENTIONAL DOSE ASCO GU 2021 Genitourinary Cancers Symposium Dose-Intensified Versus Conventional Dose-Salvage Radiotherapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: Six-Year Outcomes of the SAKK 09/10 Randomized Phase III Trial, tolerability of conventional vs. dose-intensified salvage radiation therapy, REAL-WORLD DATA DEMONSTRATES LIMITED TREATMENTCLICK TO VIEW Stephen Freedland, MD, joins Alicia Morgans, MD, MPH, to discuss a retrospective analysis of the Medicare database from January 2009-Dec 2018 on the real-world use of advanced therapies over time and the use of patterns among racial minorities that are often under-representedin clinical trials.
PROSTATE CANCER
Whole blood GRHL2 expression as a prognostic biomarker in metastatic hormone-sensitive and castration-resistant prostate cancer. May 12, 2021 First experimental evaluation of multi-target multileaf collimator tracking during volumetric modulated arc therapy forPROSTATE CANCER
How Has Prostate Cancer Radiotherapy Changed in Italy between 2004 and 2011? An Analysis of the National Patterns-Of-Practice (POP) Database by the Uro-Oncology Study Group of the Italian Society of Radiotherapy and Clinical Oncology (AIRO). June 4, 2021 Response and Toxicity to the Second Course ofCOMPLICATIONS
Complications can include urethral/scrotal events can include bleeding, urethritis, stricture, the creation of a false passage, and epididymitis. Bladder-related events can cause UTIs, bleeding, and stones. The most frequent complication of IC is a catheter-associated urinary tract infection (CAUTI). ItPROSTATE CANCER
ENZA-p trial protocol: A randomised phase II trial using PSMA as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901). May 26, 2021 Predicting Early Outcomes in Intermediate and High Risk Prostate CancerPROSTATE CANCER
Extent of High-Grade Prostatic Adenocarcinoma in Multiparametric Magnetic Resonance Imaging-Targeted Biopsy Enhances Prediction of Pathologic Stage. May 24, 2021 Characterizing Prostate-Specific Antigen Levels at Death in Patients with Metastatic Castration-Resistant Prostate Cancer: Are WePROSTATE CANCER
UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology. - Results from #20 UROALERTS - PROSTATE CANCER WEEKLY In this UroToday Journal Club, Christopher Wallis and Zachary Klaassen provide insights into the JAMA Oncology publication titled Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer: An Ancillary Study of the NRG/RTOG 9601 Randomized ClinicalTrial.
GSRGT 2020: CLINICAL TRIALS CORNER: TIGER TRIAL GSRGT 2020: Clinical Trials Corner: TIGER Trial. (Urotoday.com) The newly formed Global Society of Rare Genitourinary Tumors (GSRGT) held its inaugural meeting, focusing on penile and testicular cancer. The session held Saturday, December 12 th focused on testis cancer. In this session, the organizers convened a “Clinical Trials Corner”in
DESIGNS - INTERMITTENT CATHETERS - UROTODAY intermittent cahteters, catheter tips, coude catheter tips, atheter materials, closed catheter systems, intermittent catheters for neurogenic bladder Single-use sterile catheters are available for men and women with no coating and can be used with sterile lubricants Non-coated catheters are sited in the literature to cause an increase in urethral irritation, increased bacteriuria, long-term INDWELLING CATHETER TYPES THE LATEST PROSTATITIS RESEARCH : ABSTRACTS + "BEYOND THEPROSTATITIS TREATMENT NATURALCHRONIC BACTERIAL PROSTATITIS TREATMENTPROSTATITIS PAIN MANAGEMENTPROSTATITIS TREATMENT AAFPPROSTATITIS TREATMENT CDC Prostatitis. April 5, 2021. The efficacy and tollerability of pollen extract in combination with hyaluronic acid and vitamins in the management of patients affected by chronic prostatitis/chronic pelvic pain syndrome: a 26 weeks, randomized, controlled, single ASCO 2020: JAVELIN BLADDER 100 PHASE III RESULTSJAVELIN BLADDER 100 NEJMJAVELIN BLADDER 100 TRIAL NCT02603432 ASCO 2020 JAVELIN Bladder 100 trial, overall survival patient in patients with first line maintenance avelumab versus best supportive care in metastatic urothelial cancer JAVELIN Bladder 100, JAVELIN Bladder 100 Thomas Powles ASCO GU 2021: PRIMARY RESULTS OF EV-301: A PHASE III TRIAL ASCO GU 2021 Genitourinary Cancers Symposium Primary Results of EV-301: A Phase III Trial of Enfortumab Vedotin Versus Chemotherapy in Patients with Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma, EV-301, Enfortumab Vedotin ASCO 2020: TALAPRO-2: A PLACEBO-CONTROLLED PHASE III STUDY ASCO 2020 TALAPRO-2 trial patients with metastatic castration-resistant prostate cancer, TALAPRO-2 trial PARP inhibitor, TALAPRO-2 trial efficacy and safety, TALAPRO-2 trial patient-reportedoutcomes
COMPLICATIONS
Complications can include urethral/scrotal events can include bleeding, urethritis, stricture, the creation of a false passage, and epididymitis. Bladder-related events can cause UTIs, bleeding, and stones. The most frequent complication of IC is a catheter-associated urinary tract infection (CAUTI). It CONTEMPORARY MANAGEMENT OF NMCRPC Neal D. Shore, MD, FACS is the Medical Director for the Carolina Urologic Research Center.He practices with Atlantic Urology Clinics in Myrtle Beach, South Carolina. Dr. Shore has conducted more than 350 clinical trials, focusing mainly on GU Oncology, and serves on the Executive Boards of: Society of Urologic Oncology Board, Bladder Cancer Advocacy Network, and is Immediate SUO 2019: AN UPDATE ON CALGB 90203, RADICAL PROSTATECTOMY SUO 2019 study outcomes for CALGB 90203, study outcomes for Alliance, neoadjuvant chemohormonal therapy, radical prostatectomy, patients with clinically localized high GSRGT 2020: CLINICAL TRIALS CORNER: TIGER TRIAL GSRGT 2020: Clinical Trials Corner: TIGER Trial. (Urotoday.com) The newly formed Global Society of Rare Genitourinary Tumors (GSRGT) held its inaugural meeting, focusing on penile and testicular cancer. The session held Saturday, December 12 th focused on testis cancer. In this session, the organizers convened a “Clinical Trials Corner”in
DESIGNS - INTERMITTENT CATHETERS - UROTODAY intermittent cahteters, catheter tips, coude catheter tips, atheter materials, closed catheter systems, intermittent catheters for neurogenic bladder Single-use sterile catheters are available for men and women with no coating and can be used with sterile lubricants Non-coated catheters are sited in the literature to cause an increase in urethral irritation, increased bacteriuria, long-term INDWELLING CATHETER TYPES THE LATEST PROSTATITIS RESEARCH : ABSTRACTS + "BEYOND THEPROSTATITIS TREATMENT NATURALCHRONIC BACTERIAL PROSTATITIS TREATMENTPROSTATITIS PAIN MANAGEMENTPROSTATITIS TREATMENT AAFPPROSTATITIS TREATMENT CDC Prostatitis. April 5, 2021. The efficacy and tollerability of pollen extract in combination with hyaluronic acid and vitamins in the management of patients affected by chronic prostatitis/chronic pelvic pain syndrome: a 26 weeks, randomized, controlled, single ASCO 2020: JAVELIN BLADDER 100 PHASE III RESULTSJAVELIN BLADDER 100 NEJMJAVELIN BLADDER 100 TRIAL NCT02603432 ASCO 2020 JAVELIN Bladder 100 trial, overall survival patient in patients with first line maintenance avelumab versus best supportive care in metastatic urothelial cancer JAVELIN Bladder 100, JAVELIN Bladder 100 Thomas Powles ASCO GU 2021: PRIMARY RESULTS OF EV-301: A PHASE III TRIAL ASCO GU 2021 Genitourinary Cancers Symposium Primary Results of EV-301: A Phase III Trial of Enfortumab Vedotin Versus Chemotherapy in Patients with Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma, EV-301, Enfortumab Vedotin ASCO 2020: TALAPRO-2: A PLACEBO-CONTROLLED PHASE III STUDY ASCO 2020 TALAPRO-2 trial patients with metastatic castration-resistant prostate cancer, TALAPRO-2 trial PARP inhibitor, TALAPRO-2 trial efficacy and safety, TALAPRO-2 trial patient-reportedoutcomes
COMPLICATIONS
Complications can include urethral/scrotal events can include bleeding, urethritis, stricture, the creation of a false passage, and epididymitis. Bladder-related events can cause UTIs, bleeding, and stones. The most frequent complication of IC is a catheter-associated urinary tract infection (CAUTI). It CONTEMPORARY MANAGEMENT OF NMCRPC Neal D. Shore, MD, FACS is the Medical Director for the Carolina Urologic Research Center.He practices with Atlantic Urology Clinics in Myrtle Beach, South Carolina. Dr. Shore has conducted more than 350 clinical trials, focusing mainly on GU Oncology, and serves on the Executive Boards of: Society of Urologic Oncology Board, Bladder Cancer Advocacy Network, and is Immediate SUO 2019: AN UPDATE ON CALGB 90203, RADICAL PROSTATECTOMY SUO 2019 study outcomes for CALGB 90203, study outcomes for Alliance, neoadjuvant chemohormonal therapy, radical prostatectomy, patients with clinically localized high UROTODAY - THE GLOBAL ONLINE COMMUNITY OF UROLOGISTS June 26, 2020, marked the 20 th anniversary of the publication of the first working draft from the Human Genome Project. At a special White House event to commemorate the results of this 10-year public effort (it was really more like 50 years since the discovery of DNA, but I digress), then-President Bill Clinton called the project “the most wondrous map ever created by humankind”, andPROSTATE CANCER
How Has Prostate Cancer Radiotherapy Changed in Italy between 2004 and 2011? An Analysis of the National Patterns-Of-Practice (POP) Database by the Uro-Oncology Study Group of the Italian Society of Radiotherapy and Clinical Oncology (AIRO). June 4, 2021 Response and Toxicity to the Second Course of ASCO 2020: JAVELIN BLADDER 100 PHASE III RESULTS ASCO 2020 JAVELIN Bladder 100 trial, overall survival patient in patients with first line maintenance avelumab versus best supportive care in metastatic urothelial cancer JAVELIN Bladder 100, JAVELIN Bladder 100 Thomas PowlesPROSTATE CANCER
Validation of the new STAR-CAP prognostic group staging system in prostate cancer patients treated with radiation therapy. June 2, 2021 A Pilot Study of Multidimensional Diffusion MRI for Assessment of Tissue Heterogeneity in Prostate Cancer. JuneBLADDER CANCER
Combining Multiparametric MRI Radiomics Signature With the Vesical Imaging-Reporting and Data System (VI-RADS) Score to Preoperatively Differentiate Muscle Invasion of Bladder Cancer. June 3, 2021 Association of smoking status and recurrence of non-muscle invasive bladder cancer among patientsRENAL CANCER
Exelixis Announces Positive Phase 2 Results for cabozantinib in Combination with nivolumab in Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma at ASCO 2021 June 4, 2021 Prognostic Role of Circulating Tumor Cells (CTCS) in Metastatic Renal Cell Carcinoma: A Large, Multicenter ProspectivePROSTATE CANCER
Novel immune engagers and cellular therapies for metastatic castration-resistant prostate cancer: do we take a BiTe or ride BiKEs, TriKEs, and CARs? June 1, 2021 Oncologic impact of delaying radical prostatectomy in men with intermediate- and high-risk THE LATEST NEUROGENIC BLADDER RESEARCH : ABSTRACTS Neurogenic bladder. April 18, 2021. A consecutive series of patients undergoing trans-urethral cystolithotripsy with ballistic lithotripsy by a tertiary referral center for neurogenic bladder. Neurogenic bladder. April 11, 2021. Patient-Reported Outcomes of Bladder and Bowel Control in Children with Spina Bifida. ASCO 2021 PRESENTATIONS AND COVERAGE BEGIN JUNE 4TH Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for patients with renal cell carcinoma: Randomized, double-blind, phase III KEYNOTE-564 study. Presented By: Toni Choueiri, MD Discussion "Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for UROALERT - GU ONCOLOGY DAILY Ali Khaki and Petros Grivas come together to discuss three studies presented at the 2021 ASCO GU meeting, on immunotherapy in advanced urothelial carcinoma (aUC) as well as a recently published paper in this disease advanced bladder cancer which aimed to develop a prognostic model for overall survival (OS) in patients receiving first-line immune checkpoint inhibitors for advanced urothelial This website uses cookies to ensure you get the best experience on our website. Privacy Policy I AgreeUroToday
* Contact
* Login
* Sign Up Free
__
Menu __
Follow UroToday __ ____
* Centers of Excellence* Urologic Oncology
* Left Group
* Bladder Cancer
*
BLADDER CANCER
Ashish Kamat, MD
*
ADVANCED BLADDER CANCERPetros Grivas, MD
* Kidney Cancer
*
ADVANCED KIDNEY CANCERRana R. McKay, MD
*
KIDNEY CANCER TODAY
Sumanta (Monty) Kumar Pal, MDJaime Landman, MD
* Prostate Cancer
*
ADVANCED PROSTATE CANCER Alicia Morgans, MD, MPH*
CRPC WITH BONE METASTASESRana R. McKay, MD
*
IMAGING CENTER
Phillip Koo, MD
*
LOCALIZED PROSTATE CANCER Matthew R. Cooperberg, MD, MPH*
MCRPC TREATMENT
Charles Ryan, MD
*
MHSPC
Alicia Morgans, MD, MPH*
NMCRPC
Neal Shore, MD, FACS*
A PATIENT JOURNEY
Alicia Morgans, MD, MPHCharles J. Ryan, MD
* Upper Tract Urothelial Carcinoma*
UPPER TRACT UROTHELIAL CARCINOMA Sam S. Chang, MD, MBA * TESTICULAR, PENILE & RARE GU MALIGNANCIES*
TESTICULAR, PENILE, AND RARE GU MALIGNANCIES * Pelvic Health & Reconstruction*
BLADDER HEALTH
Diane K. Newman, DNP, ANP-BC, FAAN*
SOCIETY OF URODYNAMICS, FEMALE PELVIC MEDICINE & UROGENITAL RECONSTRUCTION (SUFU) Stephen R. Kraus, MD * Transformative Evidence* mCRPC
* CARD Trial
* PROfound Study
* mHSPC
* ENZAMET Trial
* HERO Trial
* CRPC
* PROSPER Trial
* PSMA PET Imaging
* CONDOR Trial
* OSPREY Trial
* Bladder Cancer
* Bladder Cancer Detection * Advanced Bladder Cancer * JAVELIN Bladder 100 Trial* Videos__
* Conference Coverage and Experts Group * Interviews with Experts at Conferences* ASCO 2021
* ASCO GU 2021 Bladder and Kidney Cancer * ASCO GU 2021 Prostate Cancer* ASCO 2020
* ASCO GU 2020
* ESMO 2020
* Exclusive Collaborations* APCCC 2019
* APCCC 2021
* PCF 2019
* SNMMI Curriculum
* UroToday Exclusives * Detection and Localization of Prostate Cancer: Case-Based ScanReading Review
* Provocative Questions in Prostate Cancer * A Step Towards Personalized Medicine: PSMA PET Imaging in ProstateCancer
* Clinical Trials For My Patients - Prostate Cancer * Clinical Trials For My Patients - Bladder Cancer * Clinical Trials For My Patients - Kidney Cancer * Contemporary Treatment Strategies For Androgen Deprivation TherapyIn Prostate Cancer
* COVID-19 and Genitourinary Cancers Videos* Journal Club
* Large Urology Group Practice Association (LUGPA) * Precision Medicine: PSMA Targeted Therapies in Progressive Metastatic Prostate Cancer Videos * Treatment for Bone Metastasis in CRPC - Practical Management forPatient Selection
* Urologic Oncology
* Prostate Cancer
* Advances in Nuclear Medicine, PET, and Theranostics * Advanced Prostate Cancer * Cardiovascular Disease in Men with Prostate Cancer * CRPC with Bone Metastases* The Expert Voice
* Imaging: Prostate Cancer * Localized Prostate Cancer* mCRPC
* mHSPC
* Molecular Diagnostics* Navigating Cancer
* nmCRPC
* The Patient Voice
* Precision Medicine in Prostate Cancer * Phenotypic Precision Medicine* Prostate Cancer
* Right Group
* Bladder Cancer
* Bladder Cancer
* Bladder Cancer Expert Debates * Advanced Bladder Cancer * Non-Muscle Invasive Bladder Cancer* Kidney Cancer
* Advanced Kidney Cancer* Renal Cancer
* Upper Tract Urothelial Tumors * Upper Tract Urothelial Carcinoma * Pelvic Health & Reconstruction* Bladder Health
* Indwelling Catheters * Intermittent Catheters * Lower Urinary Tract Conditions* Endourology
* Endourology Today
* Testicular Cancer
* Testicular Cancer
* Journals
*
Everyday Urology - Oncology Insights* From the Editor
* Current Issue
* Previous Issues
*
Prostate Cancer and Prostatic Diseases* From the Editor
* Current Article
* Previous Articles
* Clinical Trials__
* Clinical Trials
* Search Clinical Trials* From the Editor
* Current Letter
* Previous Letters
* Conference Coverage * Advanced Prostate Cancer Consensus Conference (APCCC) * 2019 APCCC Meeting * American Society of Clinical Oncology (ASCO) * 2021 Annual Meeting * 2021 ASCO GU Symposium * 2020 Virtual Education Program * 2020 Annual Meeting * 2020 ASCO GU Symposium * American Urological Association (AUA) * 2021 May Kick-off Weekend * 2021 Southeastern Section * 2020 Annual Meeting * ANZUP Mini Annual Scientific Meeting (ASM) * 2020 Virtual Annual Meeting * Bladder Cancer Advocacy Network (BCAN) * 2020 Think Tank Virtual Program * EAU Section of Oncological Urology* ESOU 2021
* EMUC
* 2020 Annual Meeting * European Association of Urology (EAU) * 2020 Annual Congress * European Society for Medical Oncology (ESMO) * 2020 Virtual Congress * Global Society of Rare GU Tumors* 2020 Meeting
* International Bladder Cancer Network (IBCN) * 2020 Annual Virtual Meeting * NMIBC - Drug Development 2021 * 2021 Annual Meeting * Prostate Cancer Academy * 2020 Annual Meeting * Société Internationale d'Urologie (SIU) * 2020 Annual Congress * Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)* 2021 Congress
* 2020 Congress
* Society of Urologic Oncology (SUO) * 2020 Annual Meeting * 2020 SUO - AUA Summer Webcast * Targeted Alpha Therapy (TAT)* 2019 Symposium
* International Kidney Cancer Symposium (IKCS) * 2021 European International Kidney Cancer Symposium (EIKCS)* Articles
* Urologic Oncology
* Adrenal Diseases
* Bladder Cancer
* CRPC w/ Bone Metastases* Penile Cancer
* Prostate Cancer
* Renal Cancer
* Upper Tract Tumors * Investigative Urology* Testicular Cancer
* Men's Health
* Androgen Deficiency* BPH
* Erectile Dysfunction* Male Infertility
* Peyronie’s Disease* Prostatitis
* Vasectomy
* Pelvic Health & Reconstruction * Fecal Incontinence* Fistula
* GU Trauma & Reconstruction * Indwelling Catheters* Infections
* Intermittent Catheters * Interstitial Cystitis * Neurogenic Bladder* Nocturia
* Overactive Bladder* Pelvic Prolapse
* Post-prostatectomy Incontinence * Stress Incontinence * Underactive Bladder * Urethral Strictures * Urinary Incontinence* Urinary Retention
* Urinary Tract Infection – CAUTIs * Urologic Catheters * Endourology & Urolithiasis * Minimally Invasive Procedures* Stone Disease
* Pediatric Urology
* Pediatric Urology
* COVID-19 and Genitourinary Cancers * COVID-19 and Genitourinary Cancers* Calendar
* Centers of Excellence* Urologic Oncology
* Left Group
* Bladder Cancer
*
BLADDER CANCER
Ashish Kamat, MD
*
ADVANCED BLADDER CANCERPetros Grivas, MD
* Kidney Cancer
*
ADVANCED KIDNEY CANCERRana R. McKay, MD
*
KIDNEY CANCER TODAY
Sumanta (Monty) Kumar Pal, MDJaime Landman, MD
* Prostate Cancer
*
ADVANCED PROSTATE CANCER Alicia Morgans, MD, MPH*
CRPC WITH BONE METASTASESRana R. McKay, MD
*
IMAGING CENTER
Phillip Koo, MD
*
LOCALIZED PROSTATE CANCER Matthew R. Cooperberg, MD, MPH*
MCRPC TREATMENT
Charles Ryan, MD
*
MHSPC
Alicia Morgans, MD, MPH*
NMCRPC
Neal Shore, MD, FACS*
A PATIENT JOURNEY
Alicia Morgans, MD, MPHCharles J. Ryan, MD
* Upper Tract Urothelial Carcinoma*
UPPER TRACT UROTHELIAL CARCINOMA Sam S. Chang, MD, MBA * TESTICULAR, PENILE & RARE GU MALIGNANCIES*
TESTICULAR, PENILE, AND RARE GU MALIGNANCIES * Pelvic Health & Reconstruction*
BLADDER HEALTH
Diane K. Newman, DNP, ANP-BC, FAAN*
SOCIETY OF URODYNAMICS, FEMALE PELVIC MEDICINE & UROGENITAL RECONSTRUCTION (SUFU) Stephen R. Kraus, MD * Transformative Evidence* mCRPC
* CARD Trial
* PROfound Study
* mHSPC
* ENZAMET Trial
* HERO Trial
* CRPC
* PROSPER Trial
* PSMA PET Imaging
* CONDOR Trial
* OSPREY Trial
* Bladder Cancer
* Bladder Cancer Detection * Advanced Bladder Cancer * JAVELIN Bladder 100 Trial* Videos__
* Conference Coverage and Experts Group * Interviews with Experts at Conferences* ASCO 2021
* ASCO GU 2021 Bladder and Kidney Cancer * ASCO GU 2021 Prostate Cancer* ASCO 2020
* ASCO GU 2020
* ESMO 2020
* Exclusive Collaborations* APCCC 2019
* APCCC 2021
* PCF 2019
* SNMMI Curriculum
* UroToday Exclusives * Detection and Localization of Prostate Cancer: Case-Based ScanReading Review
* Provocative Questions in Prostate Cancer * A Step Towards Personalized Medicine: PSMA PET Imaging in ProstateCancer
* Clinical Trials For My Patients - Prostate Cancer * Clinical Trials For My Patients - Bladder Cancer * Clinical Trials For My Patients - Kidney Cancer * Contemporary Treatment Strategies For Androgen Deprivation TherapyIn Prostate Cancer
* COVID-19 and Genitourinary Cancers Videos* Journal Club
* Large Urology Group Practice Association (LUGPA) * Precision Medicine: PSMA Targeted Therapies in Progressive Metastatic Prostate Cancer Videos * Treatment for Bone Metastasis in CRPC - Practical Management forPatient Selection
* Urologic Oncology
* Prostate Cancer
* Advances in Nuclear Medicine, PET, and Theranostics * Advanced Prostate Cancer * Cardiovascular Disease in Men with Prostate Cancer * CRPC with Bone Metastases* The Expert Voice
* Imaging: Prostate Cancer * Localized Prostate Cancer* mCRPC
* mHSPC
* Molecular Diagnostics* Navigating Cancer
* nmCRPC
* The Patient Voice
* Precision Medicine in Prostate Cancer * Phenotypic Precision Medicine* Prostate Cancer
* Right Group
* Bladder Cancer
* Bladder Cancer
* Bladder Cancer Expert Debates * Advanced Bladder Cancer * Non-Muscle Invasive Bladder Cancer* Kidney Cancer
* Advanced Kidney Cancer* Renal Cancer
* Upper Tract Urothelial Tumors * Upper Tract Urothelial Carcinoma * Pelvic Health & Reconstruction* Bladder Health
* Indwelling Catheters * Intermittent Catheters * Lower Urinary Tract Conditions* Endourology
* Endourology Today
* Testicular Cancer
* Testicular Cancer
* Journals
*
Everyday Urology - Oncology Insights* From the Editor
* Current Issue
* Previous Issues
*
Prostate Cancer and Prostatic Diseases* From the Editor
* Current Article
* Previous Articles
* Clinical Trials__
* Clinical Trials
* Search Clinical Trials* From the Editor
* Current Letter
* Previous Letters
* Conference Coverage * Advanced Prostate Cancer Consensus Conference (APCCC) * 2019 APCCC Meeting * American Society of Clinical Oncology (ASCO) * 2021 Annual Meeting * 2021 ASCO GU Symposium * 2020 Virtual Education Program * 2020 Annual Meeting * 2020 ASCO GU Symposium * American Urological Association (AUA) * 2021 May Kick-off Weekend * 2021 Southeastern Section * 2020 Annual Meeting * ANZUP Mini Annual Scientific Meeting (ASM) * 2020 Virtual Annual Meeting * Bladder Cancer Advocacy Network (BCAN) * 2020 Think Tank Virtual Program * EAU Section of Oncological Urology* ESOU 2021
* EMUC
* 2020 Annual Meeting * European Association of Urology (EAU) * 2020 Annual Congress * European Society for Medical Oncology (ESMO) * 2020 Virtual Congress * Global Society of Rare GU Tumors* 2020 Meeting
* International Bladder Cancer Network (IBCN) * 2020 Annual Virtual Meeting * NMIBC - Drug Development 2021 * 2021 Annual Meeting * Prostate Cancer Academy * 2020 Annual Meeting * Société Internationale d'Urologie (SIU) * 2020 Annual Congress * Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)* 2021 Congress
* 2020 Congress
* Society of Urologic Oncology (SUO) * 2020 Annual Meeting * 2020 SUO - AUA Summer Webcast * Targeted Alpha Therapy (TAT)* 2019 Symposium
* International Kidney Cancer Symposium (IKCS) * 2021 European International Kidney Cancer Symposium (EIKCS)* Articles
* Urologic Oncology
* Adrenal Diseases
* Bladder Cancer
* CRPC w/ Bone Metastases* Penile Cancer
* Prostate Cancer
* Renal Cancer
* Upper Tract Tumors * Investigative Urology* Testicular Cancer
* Men's Health
* Androgen Deficiency* BPH
* Erectile Dysfunction* Male Infertility
* Peyronie’s Disease* Prostatitis
* Vasectomy
* Pelvic Health & Reconstruction * Fecal Incontinence* Fistula
* GU Trauma & Reconstruction * Indwelling Catheters* Infections
* Intermittent Catheters * Interstitial Cystitis * Neurogenic Bladder* Nocturia
* Overactive Bladder* Pelvic Prolapse
* Post-prostatectomy Incontinence * Stress Incontinence * Underactive Bladder * Urethral Strictures * Urinary Incontinence* Urinary Retention
* Urinary Tract Infection – CAUTIs * Urologic Catheters * Endourology & Urolithiasis * Minimally Invasive Procedures* Stone Disease
* Pediatric Urology
* Pediatric Urology
* COVID-19 and Genitourinary Cancers * COVID-19 and Genitourinary Cancers* Calendar
VIDEOS
_ _ Clinical Conversations by Experts View all DETECTION AND LOCALIZATION OF PROSTATE CANCER: CASE-BASED SCAN READINGREVIEW VIDEOS
* 18F-DCFPyL and 68Ga-PSMA11 Cases - PSMA Scan Reader Training -Andrei H. Iagaru
* PSMA Radioligand Targeted Therapy - Andrei H. Iagaru * 18F-Fluciclovine - Case-based Scan Reader Training - Andrei H.Iagaru
A STEP TOWARDS PERSONALIZED MEDICINE: PSMA PET IMAGING IN PROSTATECANCER
* OSPREY and CONDOR Trials - Evaluating F-18 DCFPyL PSMA Imaging for Prostate Cancer - Michael J. Morris * The Biology of Prostate Cancer Metastasis and What PSMA Imaging Is Teaching Us: Presentation and Discussion - Kenneth J. Pienta * Diagnostic Molecular Imaging for Prostate Cancer in the United States: A Focus on Lesion Localization and Distribution Using 18F-DCFPyL PET/CT at Biochemical Recurrence Lecture & Discussion -Andrei H. Iagaru
ASCO 2021 VIDEOS
__
The Optimal Timing for Starting Avelumab Maintenance After Completing First-line Chemotherapy, JAVELIN Bladder 100 - Srikala Sridhar__ June 4, 2021
Patient Preference Study Evaluating Darolutamide and Enzalutamide in Men with mCRPC - Karim Fizazi__ June 4, 2021
Real-World Data Demonstrates Limited Treatment Intensification for Metastatic Castration-Sensitive Prostate Cancer (mCSPC) and Disparities by Race - Stephen Freedland__ June 4, 2021
Determining Dose-Limiting Toxicity and Maximum Tolerated Dose of 225Ac-J591 in Metastatic Castration-Resistant Prostate Cancer - ScottTagawa
__ June 5, 2021
Feasibility of Neoadjuvant Nivolumab Without or With Lirilumab for Muscle-Invasive Bladder Cancer (PrE0807) – Petros Grivas__ June 5, 2021
The Optimal Timing for Starting Avelumab Maintenance After Completing First-line Chemotherapy, JAVELIN Bladder 100 - Srikala Sridhar__ June 4, 2021
Patient Preference Study Evaluating Darolutamide and Enzalutamide in Men with mCRPC - Karim Fizazi__ June 4, 2021
Real-World Data Demonstrates Limited Treatment Intensification for Metastatic Castration-Sensitive Prostate Cancer (mCSPC) and Disparities by Race - Stephen Freedland__ June 4, 2021
Determining Dose-Limiting Toxicity and Maximum Tolerated Dose of 225Ac-J591 in Metastatic Castration-Resistant Prostate Cancer - ScottTagawa
__ June 5, 2021
Feasibility of Neoadjuvant Nivolumab Without or With Lirilumab for Muscle-Invasive Bladder Cancer (PrE0807) – Petros Grivas__ June 5, 2021
The Optimal Timing for Starting Avelumab Maintenance After Completing First-line Chemotherapy, JAVELIN Bladder 100 - Srikala Sridhar__ June 4, 2021
Patient Preference Study Evaluating Darolutamide and Enzalutamide in Men with mCRPC - Karim Fizazi__ June 4, 2021
Real-World Data Demonstrates Limited Treatment Intensification for Metastatic Castration-Sensitive Prostate Cancer (mCSPC) and Disparities by Race - Stephen Freedland__ June 4, 2021
__
CONTEMPORARY TREATMENT STRATEGIES FOR ADT IN PROSTATE CANCER VIDEOS__
The HERO Study – Reviewing Major Adverse Cardiovascular Results -Bertrand Tombal
__ November 8, 2020
Cardiovascular Disease and Androgen Axis - Targeted Drugs for Prostate Cancer- Javid Moslehi__ November 8, 2020
Contemporary Treatment Strategies For Androgen Deprivation Therapy In Prostate Cancer - Michael Cookson - Alicia Morgans - Fred Saad & NealShore
__ November 8, 2020
Considerations of Bone Health in Men Treated for Prostate Cancer -Fred Saad
__ November 8, 2020
Optimizing the Use of Androgen Deprivation Therapy in Men with Intermediate-Risk Prostate Cancer Presentation - Felix Feng__ November 8, 2020
The Role of ADT in Men Being Treated with Radiation Therapy - DanielSpratt
__ November 8, 2020
The HERO Study – Reviewing Major Adverse Cardiovascular Results -Bertrand Tombal
__ November 8, 2020
Cardiovascular Disease and Androgen Axis - Targeted Drugs for Prostate Cancer- Javid Moslehi__ November 8, 2020
Contemporary Treatment Strategies For Androgen Deprivation Therapy In Prostate Cancer - Michael Cookson - Alicia Morgans - Fred Saad & NealShore
__ November 8, 2020
Considerations of Bone Health in Men Treated for Prostate Cancer -Fred Saad
__ November 8, 2020
Optimizing the Use of Androgen Deprivation Therapy in Men with Intermediate-Risk Prostate Cancer Presentation - Felix Feng__ November 8, 2020
The Role of ADT in Men Being Treated with Radiation Therapy - DanielSpratt
__ November 8, 2020
The HERO Study – Reviewing Major Adverse Cardiovascular Results -Bertrand Tombal
__ November 8, 2020
Cardiovascular Disease and Androgen Axis - Targeted Drugs for Prostate Cancer- Javid Moslehi__ November 8, 2020
Contemporary Treatment Strategies For Androgen Deprivation Therapy In Prostate Cancer - Michael Cookson - Alicia Morgans - Fred Saad & NealShore
__ November 8, 2020
__
LATEST VIDEOS
__
PSMA Radioligand Targeted Therapy - Andrei H. Iagaru__ May 10, 2021
18F-DCFPyL and 68Ga-PSMA11 Cases - PSMA Scan Reader Training -Andrei H. Iagaru
__ May 10, 2021
18F-Fluciclovine - Case-based Scan Reader Training - Andrei H. Iagaru__ May 10, 2021
Determining Dose-Limiting Toxicity and Maximum Tolerated Dose of 225Ac-J591 in Metastatic Castration-Resistant Prostate Cancer - ScottTagawa
__ June 5, 2021
Feasibility of Neoadjuvant Nivolumab Without or With Lirilumab for Muscle-Invasive Bladder Cancer (PrE0807) – Petros Grivas__ June 5, 2021
A Systematic Review of the Effectiveness and Toxicities of Lutetium-177-labeled PSMA-targeted Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Journal Presentation - Christopher Wallis & Zachary Klaassen__ June 4, 2021
The Optimal Timing for Starting Avelumab Maintenance After Completing First-line Chemotherapy, JAVELIN Bladder 100 - Srikala Sridhar__ June 4, 2021
Patient Preference Study Evaluating Darolutamide and Enzalutamide in Men with mCRPC - Karim Fizazi__ June 4, 2021
Real-World Data Demonstrates Limited Treatment Intensification for Metastatic Castration-Sensitive Prostate Cancer (mCSPC) and Disparities by Race - Stephen Freedland__ June 4, 2021
Update on Urine Markers for Hematuria and Bladder Cancer - Yair Lotan__ June 1, 2021
Relugolix in the Treatment of Advanced Prostate Cancer- NeerajAgarwal
__ May 28, 2021
PYLARIFY®, F 18-labeled PSMA Targeted PET Gains US FDA Approval -Michael Morris
__ May 28, 2021
Results From the IGCCCG Update Consortium in Metastatic Seminoma And Nonseminomatous Germ Cell Tumors – Silke Gillessen__ May 24, 2021
Advances in the Treatment of Metastatic Urothelial Cancer - MatthewGalsky
__ May 24, 2021
Upper Tract Urothelial Carcinoma - Clinical Case Management –Jonathan Coleman
__ May 24, 2021
Intersection of Biology and Clinical Characteristics Towards Personalized Sequential Treatments for MIBC - Andrea Necchi and EwanGibb
__ May 14, 2021
Selection of Androgen Deprivation Therapy for Use in Advanced Prostate Cancer - Bertrand Tombal__ May 13, 2021
Assessment and Treatment of Cardiovascular Risk Factors in Veterans with Prostate Cancer - Ravi Parikh and Lova Sun__ May 12, 2021
The Treatment Landscape for Advanced Urothelial Carcinoma in 2021 -Jonathan Rosenberg
__ May 11, 2021
Real World Treatment Patterns in Locally Advanced or Metastatic Urothelial Cancer Patients - Alicia Morgans__ May 11, 2021
Novel Immune Checkpoint Axis To Understand BCG Resistance and Improve Treatment in Non-muscle Invasive Bladder Cancer - Amir Horowitz & JohnSfakianos
__ May 10, 2021
PSMA Radioligand Targeted Therapy - Andrei H. Iagaru__ May 10, 2021
18F-DCFPyL and 68Ga-PSMA11 Cases - PSMA Scan Reader Training -Andrei H. Iagaru
__ May 10, 2021
18F-Fluciclovine - Case-based Scan Reader Training - Andrei H. Iagaru__ May 10, 2021
Determining Dose-Limiting Toxicity and Maximum Tolerated Dose of 225Ac-J591 in Metastatic Castration-Resistant Prostate Cancer - ScottTagawa
__ June 5, 2021
Feasibility of Neoadjuvant Nivolumab Without or With Lirilumab for Muscle-Invasive Bladder Cancer (PrE0807) – Petros Grivas__ June 5, 2021
A Systematic Review of the Effectiveness and Toxicities of Lutetium-177-labeled PSMA-targeted Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Journal Presentation - Christopher Wallis & Zachary Klaassen__ June 4, 2021
The Optimal Timing for Starting Avelumab Maintenance After Completing First-line Chemotherapy, JAVELIN Bladder 100 - Srikala Sridhar__ June 4, 2021
Patient Preference Study Evaluating Darolutamide and Enzalutamide in Men with mCRPC - Karim Fizazi__ June 4, 2021
Real-World Data Demonstrates Limited Treatment Intensification for Metastatic Castration-Sensitive Prostate Cancer (mCSPC) and Disparities by Race - Stephen Freedland__ June 4, 2021
Update on Urine Markers for Hematuria and Bladder Cancer - Yair Lotan__ June 1, 2021
Relugolix in the Treatment of Advanced Prostate Cancer- NeerajAgarwal
__ May 28, 2021
PYLARIFY®, F 18-labeled PSMA Targeted PET Gains US FDA Approval -Michael Morris
__ May 28, 2021
Results From the IGCCCG Update Consortium in Metastatic Seminoma And Nonseminomatous Germ Cell Tumors – Silke Gillessen__ May 24, 2021
Advances in the Treatment of Metastatic Urothelial Cancer - MatthewGalsky
__ May 24, 2021
Upper Tract Urothelial Carcinoma - Clinical Case Management –Jonathan Coleman
__ May 24, 2021
Intersection of Biology and Clinical Characteristics Towards Personalized Sequential Treatments for MIBC - Andrea Necchi and EwanGibb
__ May 14, 2021
Selection of Androgen Deprivation Therapy for Use in Advanced Prostate Cancer - Bertrand Tombal__ May 13, 2021
Assessment and Treatment of Cardiovascular Risk Factors in Veterans with Prostate Cancer - Ravi Parikh and Lova Sun__ May 12, 2021
The Treatment Landscape for Advanced Urothelial Carcinoma in 2021 -Jonathan Rosenberg
__ May 11, 2021
Real World Treatment Patterns in Locally Advanced or Metastatic Urothelial Cancer Patients - Alicia Morgans__ May 11, 2021
Novel Immune Checkpoint Axis To Understand BCG Resistance and Improve Treatment in Non-muscle Invasive Bladder Cancer - Amir Horowitz & JohnSfakianos
__ May 10, 2021
PSMA Radioligand Targeted Therapy - Andrei H. Iagaru__ May 10, 2021
18F-DCFPyL and 68Ga-PSMA11 Cases - PSMA Scan Reader Training -Andrei H. Iagaru
__ May 10, 2021
18F-Fluciclovine - Case-based Scan Reader Training - Andrei H. Iagaru__ May 10, 2021
__
FEATURED VIDEOS
__
A Revolutionizing Time in Immuno-Oncology for Bladder Cancer - NealShore
__ March 14, 2018
Meeting an Unmet Need in the Nonmetastatic Castration Resistant Prostate Cancer Patient Population - Maha Hussain__ March 19, 2018
Neoadjuvant Therapy for Men with High Risk Disease Prior to Prostatectomy - Mary-Ellen Taplin __ February 23, 2018 PYLARIFY®, F 18-labeled PSMA Targeted PET Gains US FDA Approval -Michael Morris
__ May 28, 2021
Results From the IGCCCG Update Consortium in Metastatic Seminoma And Nonseminomatous Germ Cell Tumors – Silke Gillessen__ May 24, 2021
Upper Tract Urothelial Carcinoma - Clinical Case Management –Jonathan Coleman
__ May 24, 2021
Assessment and Treatment of Cardiovascular Risk Factors in Veterans with Prostate Cancer - Ravi Parikh and Lova Sun__ May 12, 2021
The Use of Blue Light Cystoscopy for Both Hospital and Outpatient Clinic - Yair Lotan and Daniel Parker__ May 5, 2021
Real-World Evidence For Patients with mCRPC Treated with Cabazitaxel- Ronald de Wit
__ May 5, 2021
Apalutamide Confirms Overall Survival Benefit at 44-Months in Metastatic Castration-Sensitive Prostate Cancer - The TITAN Study -Neeraj Agarwal
__ April 30, 2021
Survivorship in Testicular Cancer - Mary Dunn__ April 27, 2021
Practical Considerations for Administering Avelumab Maintenance in Clinical Practice - Petros Grivas and Neeraj Agarwal__ April 23, 2021
Pembrolizumab in the Real-World Setting for Non-Muscle-Invasive Bladder Cancer Unresponsive to BCG - Arjun Balar__ April 18, 2021
Facing Pelvic Pain - Elise De__ April 12, 2021
Cabazitaxel is Active in Men with mCRPC with DDR Alterations - Karim Fizazi and Mihaela Aldea__ April 11, 2021
Patient Selection for ADT Treatment with the Oral GnRH Antagonist in Clinical Practice - Ashley Ross__ March 29, 2021
The Role and Timing of Urodynamics and Certificate in Urodynamics Virtual Course - Hashim Hashim__ March 25, 2021
A Systematic Review of the Decipher® Genomic Classifier in Prostate Cancer - Ashley Ross & Daniel Spratt __ February 16, 2021 Sequential Radium-223 Treatment of mCRPC That Progressed After First-Line Novel Antihormonal Therapy, A Real-World Clinical Outcomes Study - Oliver Sartor __ February 14, 2021 Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer: COSMIC-021 - Neeraj Agarwal__ January 29, 2021
Advances from 2020 in the Management of Muscle Invasive Non-Metastatic Bladder Cancer - Bernard Bochner__ January 26, 2021
Surgical Simulator for Laparoscopic Partial Nephrectomy for Renal Cell Carcinoma - Gonzalo Vitagliano__ January 21, 2021
NCCN Guidelines Updated for Prostate Cancer M1 Systemic Therapy Based Upon The CARD Trial - Tanya Dorff__ January 18, 2021
The Accidental Journey of Shepherding PSMA PET Imaging in Prostate Cancer to the Clinic in the United States - Thomas Hope__ January 15, 2021
Clinical Implications of the Study Findings from the Radiotherapy Adjuvant Versus Early Salvage ((TROG 08.03/ANZUP RAVES) Trial - Andrew Kneebone and Declan Murphy__ January 15, 2021
Operationalizing Genomic Testing for Clinical Practice In Prostate Cancer - Jason Hafron__ January 11, 2021
The Progress and Promise of Prostate Cancer Treatments in 2020 - Charles Ryan & Alicia Morgans__ January 7, 2021
Nadofaragene Firadenovec for BCG Unresponsive NMIBC - Girish Kulkarni__ January 5, 2021
68Ga-PSMA-11 Joins FDA-Approved Tools for Management of Prostate Cancer - Thomas Hope__ December 7, 2020
Racial Differences in Genomic Profiling in Prostate Cancer - BrandonMahal
__ December 7, 2020
Overall Survival Data from the Global, Phase 3 ARAMIS Trial in Men with Non Metastatic Castration-Resistant Prostate Cancer (nmCRPC) -Karim Fizazi
__ November 10, 2020 Changing the Standard of Care in Prostate Cancer with Advances in Nuclear Medicine, PET and Theranostics Symposium - Rob Flavell__ November 3, 2020
Implications for Reducing Disparities in Muscle-Invasive Bladder Cancer - Samuel Washington III__ November 1, 2020
Interim Results from AMG 160 a half-life extended (HLE), PSMA-targeted, bispecific T-cell engager (BiTE®) immune therapy for metastatic castration-resistant prostate cancer (mCRPC) - Ben Tran__ October 5, 2020
An Expert Discussion on Gleason 6 (Grade Group 1) Prostate Cancer -Scott Eggener
__ October 4, 2020
Treatment Considerations For Disease Progression After Combination Therapy in mCRPC - Alicia Morgans __ September 29, 2020 ESMO 2020 Expert Clinical Conversation on Prostate Cancer - OliverSartor
__ September 28, 2020 The Role of FoundationOne® Liquid CDx in mCRPC - Oliver Sartor __ September 9, 2020 The Dynamic Advancements in Personalized Treatments for Metastatic Urothelial Cancer - Andrea Apolo__ August 24, 2020
DNA Repair and PARP Inhibitor Therapy in Prostate Cancer - Veda Giri, Patrick Pilié, and Arpit Rao__ July 23, 2020
Results of the SUO CTC Phase III Nadofaragene Firadenovec Trial for BCG Unresponsive NMIBC - Colin Dinney__ July 6, 2020
JAVELIN Bladder 100: Results of First-line Maintenance Therapy Plus Best Supportive Care Demonstrates Significant Prolonged OS in Advanced Urothelial Cancer - Cora Sternberg__ June 28, 2020
Therapeutic Options for Patients with Metastatic Hormone-Sensitive Prostate Cancer - Evan Yu__ June 26, 2020
Neoadjuvant Vs. Adjuvant Chemotherapy in Upper Tract Urothelial Carcinoma - Alison Birtle & Surena Matin__ June 15, 2020
A Discussion on Implementing the Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer AUA/ASCO/ASTRO/SUO Guidelines - SamChang
__ June 14, 2020
Blue Light Cystoscopy with Cysview® & Adjuvant Perioperative Chemotherapy for Nonmuscle-Invasive Bladder Cancer - Sia Daneshmand &Trinity Bivalacqua
__ June 11, 2020
Improving and Optimizing Transurethral Resection of Bladder Tumor (TURBT) Outcomes - Hugh Mostafid__ June 10, 2020
In His Own Voice: His 15-Year Journey with Advanced Prostate Cancer -Steve Poggi
__ June 9, 2020
A Debate on The Management of BCG Unresponsive - Cystectomy Ineligible Bladder Cancer Patients: Pembrolizumab Vs. Nadofaragene Firadenovec - Arjun Balar & Peter Black__ June 8, 2020
HERO Phase III Trial: Results Comparing Relugolix, an Oral GnRH Receptor Antagonist Vs. Leuprolide Acetate for Advanced ProstateCancer - Neal Shore
__ June 7, 2020
Rucaparib, A PARP Inhibitor For The Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC) - Wassim Abida__ June 3, 2020
Clinical Understanding of PARP Inhibitors in Prostate Cancer - Elena Castro, Wassim Abida, and Karen Knudsen__ June 2, 2020
IMbassador250: A Study of Atezolizumab in Combination with Enzalutamide in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) - Christopher Sweeney__ June 2, 2020
Implications of the Bacillus Calmette-Guérin (BCG) Shortage - JoshuaMeeks
__ May 12, 2020
Outcomes from The PROCEED Registry: Survival of African-American and Caucasian Men After Sipuleucel-T Immunotherapy - Oliver Sartor__ May 7, 2020
In Pursuit of Patient-Centered Care - Karen Knudsen__ May 5, 2020
Making Your Treatment Decision - Prostate Cancer Patient Interviewwith Andy Schwartz
__ May 1, 2020
Bone Health and Osteoclast Targeted Therapies in Advanced Prostate Cancer - Matthew Smith__ May 1, 2020
NCCN Localized Prostate Cancer Patient Treatment Considerations During the COVID-19 Pandemic - Edward M. Schaeffer__ April 17, 2020
NCCN Metastatic Castration-Resistant Prostate Cancer Patient Treatment Considerations During the COVID-19 Pandemic - Edward M. Schaeffer and Alicia Morgans__ April 17, 2020
Prolonging Overall Survival in Men with Non-metastatic Castration Resistant Prostate Cancer ARAMIS Trial - Neal Shore__ April 13, 2020
The ORIOLE Trial Results Discussed: Outcomes of Observation vs SABR for Oligometastatic Prostate Cancer - Phuoc T. Tran__ April 7, 2020
Moving the Field Forward, Upper Tract Urothelial Carcinoma, The POUT Study - Alison Birtle__ March 8, 2020
Implementing Prostate Cancer Working Group 3 Criteria in Clinical Trials- Michael Morris and Lawrence Schwartz __ February 25, 2020 CARD Study Demonstrates Cabazitaxel Improves Pain and Health-Related Quality of Life Analysis in Patients with mCRPC - Karim Fizazi __ February 17, 2020 A New Era In Systemic Therapies, Pembrolizumab for High Risk Non-Muscle Invasive BCG-Refractory Patients - Arjun Balar__ January 8, 2020
The VISION Trial: Radionuclide Therapy Plus Standard Therapy for Metastatic Castration Resistant Prostate Cancer - Oliver Sartor andMichael Morris
__ November 18, 2019 First-line Therapy Options for Metastatic Renal Cell Carcinoma - TianZhang
__ July 13, 2019
A Study Evaluating Optimal Use of Radioactive Drugs for Prostate Cancer Therapy - Misha Beltran__ August 2, 2019
Prospective, Real-World Data Analysis Showed Additional Overall Survival Benefit with Sipuleucel-T in African American Patients –Oliver Sartor
__ August 1, 2019
Genetic Counseling in Prostate Cancer - Brittany Szymaniak__ July 26, 2019
Darolutamide Treated Patients Maintained Quality of Life in ARAMISTrial - Fred Saad
__ August 4, 2019
Clinical Trials: Another Treatment Option for Patients - TomFarrington
__ June 24, 2019
Radium-223 in Clinical Practice - Phillip J. Koo__ August 2, 2019
Treatment Approaches in Metastatic Hormone Sensitive Prostate Cancer (mHSPC)- Alicia Morgans__ May 26, 2019
Challenges in the Diagnosis and Treatment of UTUC - Peter Black__ June 23, 2019
Theranostic Approaches for Advanced Prostate Cancer - Michael Hofman __ February 25, 2019 Immunotherapy Across Genitourinary Malignancies - James Gulley __ February 23, 2019 Optimizing ADT in Prostate Cancer Patients - Tom Keane __ February 18, 2019 Blue Light Cystoscopy for Diagnosis of Bladder Cancer - A Journal Club Review by Badrinath Konety__ January 7, 2019
High Grade Non-Muscle Invasive Bladder Cancer and BCG Refractory Patient - Josh Meeks __ September 21, 2018 CARMENA: Practice Changing Strategies for Kidney Cancer__ August 30, 2018
Survival Outcomes in Metastatic Castration-Resistant Prostate Cancer (mCRPC) for Black versus White Men-Susan Halabi__ July 25, 2018
Updates on Health-Related Quality-of-Life (HRQoL) analyses in GU Oncology - Cora Sternberg__ July 24, 2018
Nocturia in the Aging Patient, Assessment and Treatment- SusannVarano
__ July 16, 2018
Genetic Evaluation and Counseling in Prostate Cancer Treatment - Interview with Heather Cheng__ June 27, 2018
The State of Nuclear Medicine in the Treatment of Prostate Cancer - Interview with Oliver Sartor__ June 25, 2018
Update on Bladder Cancer, Current Trials and Treatments - BishoyFaltas
__ June 24, 2018
Dedication to Multidisciplinary Management of GU Oncology - AlexKutikov
__ June 12, 2018
Clinical Implications of the Abi Race Study: Interview with DanGeorge
__ June 5, 2018
Imaging Modality and Recommendations Included in RADAR 3: Interviewwith Phillip Koo
__ June 4, 2018
Personalization of Therapy to Optimize Outcomes for Men with Prostate Cancer - Interview with Felix Feng__ June 1, 2018
The Men’s Eating and Living (MEAL) Study, Diet Intervention in Men on Active Surveillance for Prostate Cancer - Interview with J. KelloggParsons
__ May 21, 2018
Geriatric Assessment of Men with Prostate Cancer - Alicia Morgans__ April 18, 2018
New Concepts in ADT- Thomas Keane__ April 8, 2018
Advances in Bladder Cancer - Systemic Therapies Including Immunotherapy - Petros Grivas__ April 8, 2018
nmCRPC - Early Treatment Leading to Favorable Outcomes - Fred Saad.__ March 22, 2018
Defining Bladder Health - Ariana Smith__ May 14, 2018
A Revolutionizing Time in Immuno-Oncology for Bladder Cancer - NealShore
__ March 14, 2018
Meeting an Unmet Need in the Nonmetastatic Castration Resistant Prostate Cancer Patient Population - Maha Hussain__ March 19, 2018
Neoadjuvant Therapy for Men with High Risk Disease Prior to Prostatectomy - Mary-Ellen Taplin __ February 23, 2018 PYLARIFY®, F 18-labeled PSMA Targeted PET Gains US FDA Approval -Michael Morris
__ May 28, 2021
Results From the IGCCCG Update Consortium in Metastatic Seminoma And Nonseminomatous Germ Cell Tumors – Silke Gillessen__ May 24, 2021
Upper Tract Urothelial Carcinoma - Clinical Case Management –Jonathan Coleman
__ May 24, 2021
Assessment and Treatment of Cardiovascular Risk Factors in Veterans with Prostate Cancer - Ravi Parikh and Lova Sun__ May 12, 2021
The Use of Blue Light Cystoscopy for Both Hospital and Outpatient Clinic - Yair Lotan and Daniel Parker__ May 5, 2021
Real-World Evidence For Patients with mCRPC Treated with Cabazitaxel- Ronald de Wit
__ May 5, 2021
Apalutamide Confirms Overall Survival Benefit at 44-Months in Metastatic Castration-Sensitive Prostate Cancer - The TITAN Study -Neeraj Agarwal
__ April 30, 2021
Survivorship in Testicular Cancer - Mary Dunn__ April 27, 2021
Practical Considerations for Administering Avelumab Maintenance in Clinical Practice - Petros Grivas and Neeraj Agarwal__ April 23, 2021
Pembrolizumab in the Real-World Setting for Non-Muscle-Invasive Bladder Cancer Unresponsive to BCG - Arjun Balar__ April 18, 2021
Facing Pelvic Pain - Elise De__ April 12, 2021
Cabazitaxel is Active in Men with mCRPC with DDR Alterations - Karim Fizazi and Mihaela Aldea__ April 11, 2021
Patient Selection for ADT Treatment with the Oral GnRH Antagonist in Clinical Practice - Ashley Ross__ March 29, 2021
The Role and Timing of Urodynamics and Certificate in Urodynamics Virtual Course - Hashim Hashim__ March 25, 2021
A Systematic Review of the Decipher® Genomic Classifier in Prostate Cancer - Ashley Ross & Daniel Spratt __ February 16, 2021 Sequential Radium-223 Treatment of mCRPC That Progressed After First-Line Novel Antihormonal Therapy, A Real-World Clinical Outcomes Study - Oliver Sartor __ February 14, 2021 Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer: COSMIC-021 - Neeraj Agarwal__ January 29, 2021
Advances from 2020 in the Management of Muscle Invasive Non-Metastatic Bladder Cancer - Bernard Bochner__ January 26, 2021
Surgical Simulator for Laparoscopic Partial Nephrectomy for Renal Cell Carcinoma - Gonzalo Vitagliano__ January 21, 2021
NCCN Guidelines Updated for Prostate Cancer M1 Systemic Therapy Based Upon The CARD Trial - Tanya Dorff__ January 18, 2021
The Accidental Journey of Shepherding PSMA PET Imaging in Prostate Cancer to the Clinic in the United States - Thomas Hope__ January 15, 2021
Clinical Implications of the Study Findings from the Radiotherapy Adjuvant Versus Early Salvage ((TROG 08.03/ANZUP RAVES) Trial - Andrew Kneebone and Declan Murphy__ January 15, 2021
Operationalizing Genomic Testing for Clinical Practice In Prostate Cancer - Jason Hafron__ January 11, 2021
The Progress and Promise of Prostate Cancer Treatments in 2020 - Charles Ryan & Alicia Morgans__ January 7, 2021
Nadofaragene Firadenovec for BCG Unresponsive NMIBC - Girish Kulkarni__ January 5, 2021
68Ga-PSMA-11 Joins FDA-Approved Tools for Management of Prostate Cancer - Thomas Hope__ December 7, 2020
Racial Differences in Genomic Profiling in Prostate Cancer - BrandonMahal
__ December 7, 2020
Overall Survival Data from the Global, Phase 3 ARAMIS Trial in Men with Non Metastatic Castration-Resistant Prostate Cancer (nmCRPC) -Karim Fizazi
__ November 10, 2020 Changing the Standard of Care in Prostate Cancer with Advances in Nuclear Medicine, PET and Theranostics Symposium - Rob Flavell__ November 3, 2020
Implications for Reducing Disparities in Muscle-Invasive Bladder Cancer - Samuel Washington III__ November 1, 2020
Interim Results from AMG 160 a half-life extended (HLE), PSMA-targeted, bispecific T-cell engager (BiTE®) immune therapy for metastatic castration-resistant prostate cancer (mCRPC) - Ben Tran__ October 5, 2020
An Expert Discussion on Gleason 6 (Grade Group 1) Prostate Cancer -Scott Eggener
__ October 4, 2020
Treatment Considerations For Disease Progression After Combination Therapy in mCRPC - Alicia Morgans __ September 29, 2020 ESMO 2020 Expert Clinical Conversation on Prostate Cancer - OliverSartor
__ September 28, 2020 The Role of FoundationOne® Liquid CDx in mCRPC - Oliver Sartor __ September 9, 2020 The Dynamic Advancements in Personalized Treatments for Metastatic Urothelial Cancer - Andrea Apolo__ August 24, 2020
DNA Repair and PARP Inhibitor Therapy in Prostate Cancer - Veda Giri, Patrick Pilié, and Arpit Rao__ July 23, 2020
Results of the SUO CTC Phase III Nadofaragene Firadenovec Trial for BCG Unresponsive NMIBC - Colin Dinney__ July 6, 2020
JAVELIN Bladder 100: Results of First-line Maintenance Therapy Plus Best Supportive Care Demonstrates Significant Prolonged OS in Advanced Urothelial Cancer - Cora Sternberg__ June 28, 2020
Therapeutic Options for Patients with Metastatic Hormone-Sensitive Prostate Cancer - Evan Yu__ June 26, 2020
Neoadjuvant Vs. Adjuvant Chemotherapy in Upper Tract Urothelial Carcinoma - Alison Birtle & Surena Matin__ June 15, 2020
A Discussion on Implementing the Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer AUA/ASCO/ASTRO/SUO Guidelines - SamChang
__ June 14, 2020
Blue Light Cystoscopy with Cysview® & Adjuvant Perioperative Chemotherapy for Nonmuscle-Invasive Bladder Cancer - Sia Daneshmand &Trinity Bivalacqua
__ June 11, 2020
Improving and Optimizing Transurethral Resection of Bladder Tumor (TURBT) Outcomes - Hugh Mostafid__ June 10, 2020
In His Own Voice: His 15-Year Journey with Advanced Prostate Cancer -Steve Poggi
__ June 9, 2020
A Debate on The Management of BCG Unresponsive - Cystectomy Ineligible Bladder Cancer Patients: Pembrolizumab Vs. Nadofaragene Firadenovec - Arjun Balar & Peter Black__ June 8, 2020
HERO Phase III Trial: Results Comparing Relugolix, an Oral GnRH Receptor Antagonist Vs. Leuprolide Acetate for Advanced ProstateCancer - Neal Shore
__ June 7, 2020
Rucaparib, A PARP Inhibitor For The Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC) - Wassim Abida__ June 3, 2020
Clinical Understanding of PARP Inhibitors in Prostate Cancer - Elena Castro, Wassim Abida, and Karen Knudsen__ June 2, 2020
IMbassador250: A Study of Atezolizumab in Combination with Enzalutamide in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) - Christopher Sweeney__ June 2, 2020
Implications of the Bacillus Calmette-Guérin (BCG) Shortage - JoshuaMeeks
__ May 12, 2020
Outcomes from The PROCEED Registry: Survival of African-American and Caucasian Men After Sipuleucel-T Immunotherapy - Oliver Sartor__ May 7, 2020
In Pursuit of Patient-Centered Care - Karen Knudsen__ May 5, 2020
Making Your Treatment Decision - Prostate Cancer Patient Interviewwith Andy Schwartz
__ May 1, 2020
Bone Health and Osteoclast Targeted Therapies in Advanced Prostate Cancer - Matthew Smith__ May 1, 2020
NCCN Localized Prostate Cancer Patient Treatment Considerations During the COVID-19 Pandemic - Edward M. Schaeffer__ April 17, 2020
NCCN Metastatic Castration-Resistant Prostate Cancer Patient Treatment Considerations During the COVID-19 Pandemic - Edward M. Schaeffer and Alicia Morgans__ April 17, 2020
Prolonging Overall Survival in Men with Non-metastatic Castration Resistant Prostate Cancer ARAMIS Trial - Neal Shore__ April 13, 2020
The ORIOLE Trial Results Discussed: Outcomes of Observation vs SABR for Oligometastatic Prostate Cancer - Phuoc T. Tran__ April 7, 2020
Moving the Field Forward, Upper Tract Urothelial Carcinoma, The POUT Study - Alison Birtle__ March 8, 2020
Implementing Prostate Cancer Working Group 3 Criteria in Clinical Trials- Michael Morris and Lawrence Schwartz __ February 25, 2020 CARD Study Demonstrates Cabazitaxel Improves Pain and Health-Related Quality of Life Analysis in Patients with mCRPC - Karim Fizazi __ February 17, 2020 A New Era In Systemic Therapies, Pembrolizumab for High Risk Non-Muscle Invasive BCG-Refractory Patients - Arjun Balar__ January 8, 2020
The VISION Trial: Radionuclide Therapy Plus Standard Therapy for Metastatic Castration Resistant Prostate Cancer - Oliver Sartor andMichael Morris
__ November 18, 2019 First-line Therapy Options for Metastatic Renal Cell Carcinoma - TianZhang
__ July 13, 2019
A Study Evaluating Optimal Use of Radioactive Drugs for Prostate Cancer Therapy - Misha Beltran__ August 2, 2019
Prospective, Real-World Data Analysis Showed Additional Overall Survival Benefit with Sipuleucel-T in African American Patients –Oliver Sartor
__ August 1, 2019
Genetic Counseling in Prostate Cancer - Brittany Szymaniak__ July 26, 2019
Darolutamide Treated Patients Maintained Quality of Life in ARAMISTrial - Fred Saad
__ August 4, 2019
Clinical Trials: Another Treatment Option for Patients - TomFarrington
__ June 24, 2019
Radium-223 in Clinical Practice - Phillip J. Koo__ August 2, 2019
Treatment Approaches in Metastatic Hormone Sensitive Prostate Cancer (mHSPC)- Alicia Morgans__ May 26, 2019
Challenges in the Diagnosis and Treatment of UTUC - Peter Black__ June 23, 2019
Theranostic Approaches for Advanced Prostate Cancer - Michael Hofman __ February 25, 2019 Immunotherapy Across Genitourinary Malignancies - James Gulley __ February 23, 2019 Optimizing ADT in Prostate Cancer Patients - Tom Keane __ February 18, 2019 Blue Light Cystoscopy for Diagnosis of Bladder Cancer - A Journal Club Review by Badrinath Konety__ January 7, 2019
High Grade Non-Muscle Invasive Bladder Cancer and BCG Refractory Patient - Josh Meeks __ September 21, 2018 CARMENA: Practice Changing Strategies for Kidney Cancer__ August 30, 2018
Survival Outcomes in Metastatic Castration-Resistant Prostate Cancer (mCRPC) for Black versus White Men-Susan Halabi__ July 25, 2018
Updates on Health-Related Quality-of-Life (HRQoL) analyses in GU Oncology - Cora Sternberg__ July 24, 2018
Nocturia in the Aging Patient, Assessment and Treatment- SusannVarano
__ July 16, 2018
Genetic Evaluation and Counseling in Prostate Cancer Treatment - Interview with Heather Cheng__ June 27, 2018
The State of Nuclear Medicine in the Treatment of Prostate Cancer - Interview with Oliver Sartor__ June 25, 2018
Update on Bladder Cancer, Current Trials and Treatments - BishoyFaltas
__ June 24, 2018
Dedication to Multidisciplinary Management of GU Oncology - AlexKutikov
__ June 12, 2018
Clinical Implications of the Abi Race Study: Interview with DanGeorge
__ June 5, 2018
Imaging Modality and Recommendations Included in RADAR 3: Interviewwith Phillip Koo
__ June 4, 2018
Personalization of Therapy to Optimize Outcomes for Men with Prostate Cancer - Interview with Felix Feng__ June 1, 2018
The Men’s Eating and Living (MEAL) Study, Diet Intervention in Men on Active Surveillance for Prostate Cancer - Interview with J. KelloggParsons
__ May 21, 2018
Geriatric Assessment of Men with Prostate Cancer - Alicia Morgans__ April 18, 2018
New Concepts in ADT- Thomas Keane__ April 8, 2018
Advances in Bladder Cancer - Systemic Therapies Including Immunotherapy - Petros Grivas__ April 8, 2018
nmCRPC - Early Treatment Leading to Favorable Outcomes - Fred Saad.__ March 22, 2018
Defining Bladder Health - Ariana Smith__ May 14, 2018
A Revolutionizing Time in Immuno-Oncology for Bladder Cancer - NealShore
__ March 14, 2018
Meeting an Unmet Need in the Nonmetastatic Castration Resistant Prostate Cancer Patient Population - Maha Hussain__ March 19, 2018
Neoadjuvant Therapy for Men with High Risk Disease Prior to Prostatectomy - Mary-Ellen Taplin __ February 23, 2018__
Transformative Evidence Level 1 Evidence: Practice-Changing Clinical Trials View allPROFOUND STUDY
Survival with Olaparib in Metastatic Castration-Resistant ProstateCancer.
We previously reported that olaparib led to significantly longer imaging-based progression-free survival than the physician's choice of enzalutamide or abiraterone among men with metastatic castration-resistant prostate cancer who had qualifying alterations in homologous recombination repair genes and whose disease had progressed during previous treatment with a next-generation hormonal agent.Read More
HERO STUDY
Oral Relugolix for Androgen-Deprivation Therapy in Advanced ProstateCancer
Injectable luteinizing hormone–releasing hormone agonists (e.g., leuprolide) are the standard agents for achieving androgen deprivation for prostate cancer despite the initial testosterone surge and delay in therapeutic effect. The efficacy and safety of relugolix, an oral gonadotropin-releasing hormone antagonist, as compared with those of leuprolide are not known. Read MoreConference Coverage
Conference Highlights from Recent Conference Coverage__
ASCO 2020: Efficacy and Safety in Older Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Cabazitaxel versus Abiraterone or Enzalutamide in the CARD Study Presented by CORA N. STERNBERG, MD, FACP Prostate cancer is the 2nd and 3rd leading cause of cancer death in the USA and in Europe, respectively,1,2 with most deaths occurring in men over the age of 75. In men with metastatic castrate-resistant prostate cancer (mCRPC), there are multiple treatment options available today, Read More ASCO 2020: Health-Related Quality of Life for Olaparib versus Enzalutamide or Abiraterone in mCRPC with Homologous Recombination Repair Gene Alterations: PROfound Presented by ANTOINE THIERY-VUILLEMIN, MD, PHD The randomized Phase 3 PROfound trial showed that olaparib significantly prolonged radiographic progression-free survival compared with physician’s choice of new hormonal agent (enzalutamide or abiraterone) in men with mCRPC and HRR gene alterations, whose disease had progressed on prior new hormonal agent. Read More ASCO GU 2021: First Results from the Phase 3 CheckMate 274 Trial of Adjuvant Nivolumab vs Placebo in Patients Who Underwent Radical Surgery for High-Risk Muscle-Invasive Urothelial Carcinoma Presented by DEAN F. BAJORIN, MD For patients with muscle-invasive bladder cancer who are eligible for curative-intent treatment, cisplatin-based neoadjuvant chemotherapy (NAC) followed by radical cystectomy (RC) is a standard of care with improved pathologic response and overall survival (OS) compared to RCalone. Read More
ASCO GU 2021: Enfortumab Vedotin in Previously Treated Urothelial Cancer - Results of EV-301 & EV-201 Cohort 2 Discussion Presented by ARLENE O. SIEFKER-RADTKE, MD In this presentation, Arlene O. Siefker-Radtke, MD provided a discussion on two presentations on Enfortumab Vedotin (EV) in previously treated urothelial cancer. Primary results of EV-301 and EV-201 Cohort 2: Enfortumab vedotin in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer who received prior PD-1/PD-L1 inhibitors.Read More
ASCO GU 2021: Radical Cystectomy for High-Risk Non-Muscle-Invasive Bladder Cancer: Who and Why? Presented by ANNE K. SCHUCKMAN, MD The optimizing personalized management of non-muscle-invasive bladder cancer session at the 2021 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) included a presentation from Dr. Anne Schuckman discussing which patients with high-risk non-muscle-invasive bladder cancer may benefit from radical cystectomy. Read More ASCO GU 2021: TIVO-3: Tivozanib in Patients with Advanced Renal Cell Carcinoma Who Have Progressed After Treatment with Axitinib Presented by BRIAN I. RINI, MD The activity of tivozanib after axitinib has not been previously defined, and as such the activity of tivozanib after prior therapy types including axitinib is of clinical relevance. At the 2021 ASCO GU, Dr. Brian Rini and colleagues presented results of the TIVO-3 trial testing tivozanib in patients with advanced RCC who had progressed after prior axitinib treatment. Read More ASCO GU 2021: Patient-Reported Outcomes Of Patients With Advanced Renal Cell Carcinoma Treated With First-Line Nivolumab Plus Cabozantinib Versus Sunitinib: The Checkmate 9ER Trial Presented by DAVID CELLA, PHD The treatment landscape for first-line therapy among patients with metastatic renal cell carcinoma (mRCC) has changed dramatically over the past 2 years. In 2018, publication of the CheckMate214 data demonstrated a survival benefit for patients treated with nivolumab and ipilimumab compared with sunitinib in intermediate and poor-risk mRCC, ushering in the immunotherapy era for mRCC. Read More ASCO GU 2021: Clinical Conundrums of Genomically Driven Prostate Cancer - Case Panel Discussion Presented by MICHAEL J. MORRIS, MD The case presented was that of a 54-year-old man with an extensive family history of cancer. His mother died from ovarian cancer, his father had prostate cancer and died of colon cancer, his brother developed kidney and prostate cancer, and his sister had breast and ovarian cancer. Read More ASCO GU 2021: Genomic Landscape of Advanced Prostate Cancer In Racial Minority Populations: Real-World Experience In A Safety-Net HospitalOncology Clinic
Presented by TAMER KHASHAB, MD In this study, Dr. Khashab presented genomic data derived from a retrospective analysis of patients treated at a community-focused academic healthcare system in Texas that serves a higher percentage of Hispanic and African American patients with prostate cancer. ReadMore
ASCO GU 2021: TROPiCS-04: Study of Sacituzumab Govitecan in Metastatic Or Locally Advanced Unresectable Urothelial Cancer That Has Progressed After Platinum and Checkpoint Inhibitor Therapy Presented by PETROS GRIVAS, MD, PH.D. In a presentation at the 2021 ASCO GU, Dr. Grivas described the design of the confirmatory phase III trial, TROPiCS-04. TROPiCS-04 is a global, multicenter, open-label, randomized controlled trial, performed among patients with locally advanced unresectable or metastatic urothelial carcinoma. Read More ASCO GU 2021: Clinical Outcomes of Patients With mCRPC Receiving Radium-223 Early Versus Late in the Treatment Sequence Presented by LAWRENCE MBUAGBAW, MD, MPH, PH.D. At the 2021 ASCO GU, Dr. Lawrence Mbuagbaw and colleagues presented results of their real-world study evaluating clinical outcomes of patients when Radium-223 was used early (second-line) or late (third or later lines) among men with mCRPC. Read More ASCO GU 2021: The Impact of Concomitant Prostate Cancer Therapy on Efficacy and Safety of Relugolix vs Leuprolide in Men With Advanced Prostate Cancer: Subgroup Analysis, the Phase III HERO Study Presented by DANIEL J. GEORGE, MD Dr. Daniel George and colleagues presented a subgroup analysis assessing the impact of concomitant prostate cancer therapy on the safety and efficacy of the oral GnRH receptor antagonist relugolix versus leuprolide in men with advanced prostate cancer. Read More ANZUP Mini ASM 2020: ANZUP Trial Update - The ENZAMET Trial Presented by IAN DAVIS, MBBS, PHD, FRACP, FACHPM The 2020 Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) Mini Annual Scientific Meeting featured a session on ANZUP trial updates, including an update of the critical Phase IIIENZAMET
trial provided by Drs. Ian Davis, Arun Azad, and Lisa Horvath. ReadMore
EMUC 2020: Neoadjuvant Versus Adjuvant Strategies in Locally AdvancedBladder Cancer
Presented by ANDREA NECCHI, MD, In an oral presentation in a session examining neoadjuvant versus adjuvant strategies in locally advanced bladder cancer at the 12th European Multidisciplinary Congress on Urological Cancers (EMUC), Dr. Andrea Necchi led a discussion of neoadjuvant strategies in advanced bladder cancer. Read More ESMO Virtual Congress 2020: DASL-HiCaP: Darolutamide Augments Standard Therapy for Localized Very High-Risk Cancer of the Prostate(ANZUP 1801)
Presented by TAMIM NIAZI, MDCM Patients with high-risk localized prostate cancer who receive radiotherapy for management of their primary disease also receive LHRH analog therapy for at least one year or longer. Read More ESMO Virtual Congress 2020: EV-302: Enfortumab Vedotin plus Pembrolizumab and/or Chemotherapy, vs Chemotherapy Alone, in Untreated Locally Advanced or Metastatic Urothelial Cancer Presented by MICHIEL S. VAN DER HEIJDEN, MD, PHD Platinum-based chemotherapy is the mainstay of first-line treatment for medically eligible patients with advanced urothelial carcinoma (UC). Unfortunately, up to 50% of patients are unable to receive cisplatin, and disease progression often develops even for patients who receive cisplatin. Read More ESMO Virtual Congress 2020: Treatment in CARD Eligible Metastatic Castration Resistant Prostate Cancer Patients According to the Status of Germline HRR Mutations: Cabazitaxel vs Enzalutamide/Abiraterone Presented by CASILDA LLACER PEREZ, MDThe CARD
trial was a randomized open-label study of cabazitaxel versus the alternative anti-androgen therapy in patients with metastatic castration resistant prostate cancer (mCRPC) who had progressed on docetaxel and also progressed on either enzalutamide or abiraterone within 12 months of therapy initiation. Read More ESMO Virtual Congress 2020: Results of the PSMA/CD3 BiTE AMG 160 in the Context of Immunotherapy for Metastatic Castration-Resistant Prostate Cancer (mCRPC) Presented by CORA STERNBERG, MD Many immunotherapy strategies have been pursued in metastatic castration-resistant prostate cancer (mCRPC) to date, with the dendritic cell vaccine sipuleucel-T representing the only approved therapy in this space. Read More ESMO Virtual Congress 2020: First Results from a Phase 1 Study of AMG 160, a Half-Life Extended, PSMA-Targeted, Bispecific T-Cell Engager (BiTE®) Immune Therapy for Metastatic Castration-Resistant ProstateCancer
Presented by BEN TRAN, MBBS, FRACP There is an urgency to develop therapies with novel mechanisms of action to treat prostate cancers resistant to chemohormonal and radiation therapies. Unfortunately, to date, immune therapies have offered limited efficacy in patients with metastatic castration-resistant prostate cancer (mCRPC). Read More ESMO Virtual Congress 2020: TROPHY-U-01 Cohort 1 Final Results: A Phase 2 Study of Sacituzumab Govitecan (SG) in Metastatic Urothelial Cancer That Has Progressed After Platinum and Checkpoint Inhibitors Presented by YOHANN LORIOT, MD, MSC Treatment options for advanced urothelial cancer that has progressed through platinum chemotherapy and immune checkpoint blockade consist of (1) single agent chemotherapy, (2) FGFR inhibitor therapyfor tumors harboring susceptible alterations, and (3) the antibody-drug conjugate enfortumab vedotin. Read More ESMO Virtual Congress 2020: Nivolumab + Cabozantinib vs Sunitinib in First-line Treatment for Advanced Renal Cell Carcinoma: First Results From The Randomized Phase 3 CheckMate 9ER Trial Presented by TONI K. CHOUEIRI, MD The treatment landscape for first-line therapy among patients with metastatic renal cell carcinoma (mRCC) has changed dramatically over the past 2 years. Read More ESMO Virtual Congress 2020: Neutrophil-Lymphocyte Ratio as a Prognostic and Predictive Biomarker in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Cabazitaxel vs. Abiraterone or Enzalutamide in the CARD Study Presented by RONALD DE WIT PHD (UroToday.com) It is well known that inflammation is a hallmark of cancer, harboring a critical role in tumor development and metastatic progression in many cancers, including prostate cancer. Read More ASCO 2020: JAVELIN Bladder 100 Phase III Results: Maintenance Avelumab + Best Supportive Care vs BSC Alone After Platinum-Based First-Line Chemotherapy in Advanced Urothelial Carcinoma Presented by THOMAS POWLES, MBBS, MRCP, MD Advanced urothelial carcinoma resulted in over 200,000 deaths across the world in 2018. Though the majority of patients eligible for such therapy respond to platinum-based chemotherapy, disease progression occurs relatively quickly and half or less of patients receive second line treatment. Read More ASCO 2020: A Phase III Trial of Docetaxel versus Docetaxel and Radium-223 in Patients with mCRPC: DORA Presented by MICHAEL J. MORRIS, MD Radium-223 is a bone-targeted alpha therapy that prolongs survival in patients with symptomatic metastatic castration-resistant prostate cancer (mCRPC) to the bone based on results from the phase III ALSYMPCA trial. Read More ASCO 2020: Results from a Phase III, Prospective, Multicenter Study (CONDOR): Impact of PSMA-Targeted Imaging with 18F-DCFPyL-PET/CT on Clinical Management of Patients with Biochemically Recurrent ProstateCancer
Presented by MICHAEL J. MORRIS, MD Biochemical recurrence is not an infrequent occurrence following local therapy for prostate cancer, utilizing either radiotherapy or radical prostatectomy. Following biochemical relapse, patients may have disease either locally in the pelvic or more distantly. Read More ASCO 2020: CARD: Overall Survival Analysis of Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Cabazitaxelversus Abiraterone
Presented by BERTRAND F. TOMBAL, MD, PHDThe CARD
trial, initially presented at ESMO 2019and
subsequently published, addressed the question of appropriate third line therapy in mCRPC for patients who had previously received docetaxel and also progressed on an anti-androgen therapy (either abiraterone or enzalutamide) within 12 months. Read More ASCO 2020: Efficacy and Safety in Older Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Cabazitaxel versus Abiraterone or Enzalutamide in the CARD Study Presented by CORA N. STERNBERG, MD, FACP Prostate cancer is the 2nd and 3rd leading cause of cancer death in the USA and in Europe, respectively,1,2 with most deaths occurring in men over the age of 75. In men with metastatic castrate-resistant prostate cancer (mCRPC), there are multiple treatment options available today, Read More ASCO 2020: Health-Related Quality of Life for Olaparib versus Enzalutamide or Abiraterone in mCRPC with Homologous Recombination Repair Gene Alterations: PROfound Presented by ANTOINE THIERY-VUILLEMIN, MD, PHD The randomized Phase 3 PROfound trial showed that olaparib significantly prolonged radiographic progression-free survival compared with physician’s choice of new hormonal agent (enzalutamide or abiraterone) in men with mCRPC and HRR gene alterations, whose disease had progressed on prior new hormonal agent. Read More ASCO GU 2021: First Results from the Phase 3 CheckMate 274 Trial of Adjuvant Nivolumab vs Placebo in Patients Who Underwent Radical Surgery for High-Risk Muscle-Invasive Urothelial Carcinoma Presented by DEAN F. BAJORIN, MD For patients with muscle-invasive bladder cancer who are eligible for curative-intent treatment, cisplatin-based neoadjuvant chemotherapy (NAC) followed by radical cystectomy (RC) is a standard of care with improved pathologic response and overall survival (OS) compared to RCalone. Read More
ASCO GU 2021: Enfortumab Vedotin in Previously Treated Urothelial Cancer - Results of EV-301 & EV-201 Cohort 2 Discussion Presented by ARLENE O. SIEFKER-RADTKE, MD In this presentation, Arlene O. Siefker-Radtke, MD provided a discussion on two presentations on Enfortumab Vedotin (EV) in previously treated urothelial cancer. Primary results of EV-301 and EV-201 Cohort 2: Enfortumab vedotin in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer who received prior PD-1/PD-L1 inhibitors.Read More
ASCO GU 2021: Radical Cystectomy for High-Risk Non-Muscle-Invasive Bladder Cancer: Who and Why? Presented by ANNE K. SCHUCKMAN, MD The optimizing personalized management of non-muscle-invasive bladder cancer session at the 2021 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) included a presentation from Dr. Anne Schuckman discussing which patients with high-risk non-muscle-invasive bladder cancer may benefit from radical cystectomy. Read More ASCO GU 2021: TIVO-3: Tivozanib in Patients with Advanced Renal Cell Carcinoma Who Have Progressed After Treatment with Axitinib Presented by BRIAN I. RINI, MD The activity of tivozanib after axitinib has not been previously defined, and as such the activity of tivozanib after prior therapy types including axitinib is of clinical relevance. At the 2021 ASCO GU, Dr. Brian Rini and colleagues presented results of the TIVO-3 trial testing tivozanib in patients with advanced RCC who had progressed after prior axitinib treatment. Read More ASCO GU 2021: Patient-Reported Outcomes Of Patients With Advanced Renal Cell Carcinoma Treated With First-Line Nivolumab Plus Cabozantinib Versus Sunitinib: The Checkmate 9ER Trial Presented by DAVID CELLA, PHD The treatment landscape for first-line therapy among patients with metastatic renal cell carcinoma (mRCC) has changed dramatically over the past 2 years. In 2018, publication of the CheckMate214 data demonstrated a survival benefit for patients treated with nivolumab and ipilimumab compared with sunitinib in intermediate and poor-risk mRCC, ushering in the immunotherapy era for mRCC. Read More ASCO GU 2021: Clinical Conundrums of Genomically Driven Prostate Cancer - Case Panel Discussion Presented by MICHAEL J. MORRIS, MD The case presented was that of a 54-year-old man with an extensive family history of cancer. His mother died from ovarian cancer, his father had prostate cancer and died of colon cancer, his brother developed kidney and prostate cancer, and his sister had breast and ovarian cancer. Read More ASCO GU 2021: Genomic Landscape of Advanced Prostate Cancer In Racial Minority Populations: Real-World Experience In A Safety-Net HospitalOncology Clinic
Presented by TAMER KHASHAB, MD In this study, Dr. Khashab presented genomic data derived from a retrospective analysis of patients treated at a community-focused academic healthcare system in Texas that serves a higher percentage of Hispanic and African American patients with prostate cancer. ReadMore
ASCO GU 2021: TROPiCS-04: Study of Sacituzumab Govitecan in Metastatic Or Locally Advanced Unresectable Urothelial Cancer That Has Progressed After Platinum and Checkpoint Inhibitor Therapy Presented by PETROS GRIVAS, MD, PH.D. In a presentation at the 2021 ASCO GU, Dr. Grivas described the design of the confirmatory phase III trial, TROPiCS-04. TROPiCS-04 is a global, multicenter, open-label, randomized controlled trial, performed among patients with locally advanced unresectable or metastatic urothelial carcinoma. Read More ASCO GU 2021: Clinical Outcomes of Patients With mCRPC Receiving Radium-223 Early Versus Late in the Treatment Sequence Presented by LAWRENCE MBUAGBAW, MD, MPH, PH.D. At the 2021 ASCO GU, Dr. Lawrence Mbuagbaw and colleagues presented results of their real-world study evaluating clinical outcomes of patients when Radium-223 was used early (second-line) or late (third or later lines) among men with mCRPC. Read More ASCO GU 2021: The Impact of Concomitant Prostate Cancer Therapy on Efficacy and Safety of Relugolix vs Leuprolide in Men With Advanced Prostate Cancer: Subgroup Analysis, the Phase III HERO Study Presented by DANIEL J. GEORGE, MD Dr. Daniel George and colleagues presented a subgroup analysis assessing the impact of concomitant prostate cancer therapy on the safety and efficacy of the oral GnRH receptor antagonist relugolix versus leuprolide in men with advanced prostate cancer. Read More ANZUP Mini ASM 2020: ANZUP Trial Update - The ENZAMET Trial Presented by IAN DAVIS, MBBS, PHD, FRACP, FACHPM The 2020 Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) Mini Annual Scientific Meeting featured a session on ANZUP trial updates, including an update of the critical Phase IIIENZAMET
trial provided by Drs. Ian Davis, Arun Azad, and Lisa Horvath. ReadMore
EMUC 2020: Neoadjuvant Versus Adjuvant Strategies in Locally AdvancedBladder Cancer
Presented by ANDREA NECCHI, MD, In an oral presentation in a session examining neoadjuvant versus adjuvant strategies in locally advanced bladder cancer at the 12th European Multidisciplinary Congress on Urological Cancers (EMUC), Dr. Andrea Necchi led a discussion of neoadjuvant strategies in advanced bladder cancer. Read More ESMO Virtual Congress 2020: DASL-HiCaP: Darolutamide Augments Standard Therapy for Localized Very High-Risk Cancer of the Prostate(ANZUP 1801)
Presented by TAMIM NIAZI, MDCM Patients with high-risk localized prostate cancer who receive radiotherapy for management of their primary disease also receive LHRH analog therapy for at least one year or longer. Read More ESMO Virtual Congress 2020: EV-302: Enfortumab Vedotin plus Pembrolizumab and/or Chemotherapy, vs Chemotherapy Alone, in Untreated Locally Advanced or Metastatic Urothelial Cancer Presented by MICHIEL S. VAN DER HEIJDEN, MD, PHD Platinum-based chemotherapy is the mainstay of first-line treatment for medically eligible patients with advanced urothelial carcinoma (UC). Unfortunately, up to 50% of patients are unable to receive cisplatin, and disease progression often develops even for patients who receive cisplatin. Read More ESMO Virtual Congress 2020: Treatment in CARD Eligible Metastatic Castration Resistant Prostate Cancer Patients According to the Status of Germline HRR Mutations: Cabazitaxel vs Enzalutamide/Abiraterone Presented by CASILDA LLACER PEREZ, MDThe CARD
trial was a randomized open-label study of cabazitaxel versus the alternative anti-androgen therapy in patients with metastatic castration resistant prostate cancer (mCRPC) who had progressed on docetaxel and also progressed on either enzalutamide or abiraterone within 12 months of therapy initiation. Read More ESMO Virtual Congress 2020: Results of the PSMA/CD3 BiTE AMG 160 in the Context of Immunotherapy for Metastatic Castration-Resistant Prostate Cancer (mCRPC) Presented by CORA STERNBERG, MD Many immunotherapy strategies have been pursued in metastatic castration-resistant prostate cancer (mCRPC) to date, with the dendritic cell vaccine sipuleucel-T representing the only approved therapy in this space. Read More ESMO Virtual Congress 2020: First Results from a Phase 1 Study of AMG 160, a Half-Life Extended, PSMA-Targeted, Bispecific T-Cell Engager (BiTE®) Immune Therapy for Metastatic Castration-Resistant ProstateCancer
Presented by BEN TRAN, MBBS, FRACP There is an urgency to develop therapies with novel mechanisms of action to treat prostate cancers resistant to chemohormonal and radiation therapies. Unfortunately, to date, immune therapies have offered limited efficacy in patients with metastatic castration-resistant prostate cancer (mCRPC). Read More ESMO Virtual Congress 2020: TROPHY-U-01 Cohort 1 Final Results: A Phase 2 Study of Sacituzumab Govitecan (SG) in Metastatic Urothelial Cancer That Has Progressed After Platinum and Checkpoint Inhibitors Presented by YOHANN LORIOT, MD, MSC Treatment options for advanced urothelial cancer that has progressed through platinum chemotherapy and immune checkpoint blockade consist of (1) single agent chemotherapy, (2) FGFR inhibitor therapyfor tumors harboring susceptible alterations, and (3) the antibody-drug conjugate enfortumab vedotin. Read More ESMO Virtual Congress 2020: Nivolumab + Cabozantinib vs Sunitinib in First-line Treatment for Advanced Renal Cell Carcinoma: First Results From The Randomized Phase 3 CheckMate 9ER Trial Presented by TONI K. CHOUEIRI, MD The treatment landscape for first-line therapy among patients with metastatic renal cell carcinoma (mRCC) has changed dramatically over the past 2 years. Read More ESMO Virtual Congress 2020: Neutrophil-Lymphocyte Ratio as a Prognostic and Predictive Biomarker in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Cabazitaxel vs. Abiraterone or Enzalutamide in the CARD Study Presented by RONALD DE WIT PHD (UroToday.com) It is well known that inflammation is a hallmark of cancer, harboring a critical role in tumor development and metastatic progression in many cancers, including prostate cancer. Read More ASCO 2020: JAVELIN Bladder 100 Phase III Results: Maintenance Avelumab + Best Supportive Care vs BSC Alone After Platinum-Based First-Line Chemotherapy in Advanced Urothelial Carcinoma Presented by THOMAS POWLES, MBBS, MRCP, MD Advanced urothelial carcinoma resulted in over 200,000 deaths across the world in 2018. Though the majority of patients eligible for such therapy respond to platinum-based chemotherapy, disease progression occurs relatively quickly and half or less of patients receive second line treatment. Read More ASCO 2020: A Phase III Trial of Docetaxel versus Docetaxel and Radium-223 in Patients with mCRPC: DORA Presented by MICHAEL J. MORRIS, MD Radium-223 is a bone-targeted alpha therapy that prolongs survival in patients with symptomatic metastatic castration-resistant prostate cancer (mCRPC) to the bone based on results from the phase III ALSYMPCA trial. Read More ASCO 2020: Results from a Phase III, Prospective, Multicenter Study (CONDOR): Impact of PSMA-Targeted Imaging with 18F-DCFPyL-PET/CT on Clinical Management of Patients with Biochemically Recurrent ProstateCancer
Presented by MICHAEL J. MORRIS, MD Biochemical recurrence is not an infrequent occurrence following local therapy for prostate cancer, utilizing either radiotherapy or radical prostatectomy. Following biochemical relapse, patients may have disease either locally in the pelvic or more distantly. Read More ASCO 2020: CARD: Overall Survival Analysis of Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Cabazitaxelversus Abiraterone
Presented by BERTRAND F. TOMBAL, MD, PHDThe CARD
trial, initially presented at ESMO 2019and
subsequently published, addressed the question of appropriate third line therapy in mCRPC for patients who had previously received docetaxel and also progressed on an anti-androgen therapy (either abiraterone or enzalutamide) within 12 months. Read More ASCO 2020: Efficacy and Safety in Older Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Cabazitaxel versus Abiraterone or Enzalutamide in the CARD Study Presented by CORA N. STERNBERG, MD, FACP Prostate cancer is the 2nd and 3rd leading cause of cancer death in the USA and in Europe, respectively,1,2 with most deaths occurring in men over the age of 75. In men with metastatic castrate-resistant prostate cancer (mCRPC), there are multiple treatment options available today, Read More ASCO 2020: Health-Related Quality of Life for Olaparib versus Enzalutamide or Abiraterone in mCRPC with Homologous Recombination Repair Gene Alterations: PROfound Presented by ANTOINE THIERY-VUILLEMIN, MD, PHD The randomized Phase 3 PROfound trial showed that olaparib significantly prolonged radiographic progression-free survival compared with physician’s choice of new hormonal agent (enzalutamide or abiraterone) in men with mCRPC and HRR gene alterations, whose disease had progressed on prior new hormonal agent. Read More__
Everyday Urology™ – Oncology Insights Review Articles Focusing on Urologic Oncology View all EVERYDAY UROLOGY: VOLUME 5, ISSUE 4 * The Evolving Landscape of First-Line Therapy for Metastatic Clear Cell Renal Cell Carcinoma By Christopher J.D. Wallis, MD, PhD and Zachary Klaassen, MD, MSc * Post-Operative Radiotherapy in Prostate Cancer – The State ofthe Data
By Christopher J.D. Wallis, MD, PhD and Zachary Klaassen, MD, MSc * Spotlight: International Bladder Cancer Network (IBCN) 2020 and Société Internationale d'Urologie (SIU) Virtual Conference 2020 Download Current Issue×
Everyday Urology
DOWNLOAD VOLUME 5, ISSUE 4First Name required
Last Name required
Work Email required
Organization requiredJob Title required
Yes, I want to subscribe to email updates from UroToday Get yourcopy!
Library Resources
The State-of-the-Evidence in Brief Reviews by Experts__
Appropriate Use Criteria for Imaging Evaluation of Biochemical Recurrence of Prostate Cancer After Definitive Primary TreatmentMay 20, 2020
The purpose of this document is to describe the appropriate use of imaging in the diagnostic evaluation of patients with BCR after definitive primary treatment. The imaging modalities that were considered included CT, bone scan, and the U.S. Food and Drug Administration (FDA)–approved PET radiotracers that track malignancy-induced lipogenesis (11C-choline) and amino acid metabolism (18F-fluciclovine). Read More Risks of Delaying Bladder Cancer Diagnosis- Surveillance and SurgeryDuring COVID-19
Written by CHRISTOPHER J.D. WALLIS, MD, PHD AND ZACHARY KLAASSEN, MD,MSC
April 20, 2020
The rapid spread of Coronavirus Disease 2019 (COVID-19), caused by the betacoronavirus SARS-CoV-2, throughout the world has had dramatic effects on healthcare systems with impacts far beyond the patients actually infected with COVID-19. Patients who manifest severe forms of COVID-19 requiring respiratory support typically require this for prolonged durations,Read More
PARP Inhibitors, Prostate Cancer and a Promise Fulfilled Written by CHARLES RYAN, MDJune 30, 2020
June 26, 2020, marked the 20th anniversary of the publication of the first working draft from the Human Genome Project. At a special White House event to commemorate the results of this 10-year public effort (it was really more like 50 years since the discovery of DNA, but I digress), then-President Bill Clinton called the project “the most wondrous map ever created by humankind”, and touted its promise to detect, prevent, and treat disease. Read More Biomarker Strategies for Prostate Cancer Care During COVID-19June 24, 2020
Despite the recent disruptions in health care delivery due to the COVID-19 pandemic, patients at risk for developing prostate cancer as well as those diagnosed with prostate cancer still deserve timely and optimal decision making. Unfortunately, the uncertainty of the pandemic requires urologists to adopt innovative strategies in order to prioritize patient care while being mindful to mitigate the potential infectious risks of COVID-19 to their patients as well as to their healthcare team.Read More
PARP Inhibitors - A Breakthrough in Targeted Therapies for ProstateCancer
Written by ARPIT RAO, MBBS AND CHARLES RYAN, MDJune 29, 2020
In this review, we will summarize the current indications for PARP inhibitor monotherapies and combination(s), review data from clinical trials in prostate cancer, discuss management of commonly encountered side effects, and highlight exciting clinical research on expanding the role of PARP inhibitors in prostate cancer. Read More Germline Testing for DNA Repair Mutations in Prostate Cancer: Who,When and How?
Written by VEDA N. GIRI, MDJune 29, 2020
Understanding the role of germline testing in prostate cancer is now critical to urologic and oncology practice for metastatic castration-resistant prostate cancer. Here, we will address who should be considered for germline testing, when germline testing may influence treatment and management, and _how_ to implement germline testing involving provider practices and genetic counseling. Read More What Are the Most Common Genomic Aberrations Seen in DNA Damage Response (DDR) Pathways in Advanced Prostate Cancer? Written by PATRICK G. PILIÉ, MDJune 29, 2020
Men with advanced prostate cancer have a 10-15% risk of carrying a hereditary, or germline, variant in a DNA damage response gene. Pathogenic or deleterious variants in these same DNA damage response genes can also be found at the somatic, or tumor-associated level, in up to 25% of metastatic castrate-resistant prostate cancer. Read More PARP Inhibitors in Prostate Cancer: PROfound and Beyond Written by CHRISTOPHER J.D. WALLIS, MD, PHD AND ZACHARY KLAASSEN, MD,MSC
June 17, 2020
Prostate cancer is a clinically heterogeneous disease with many patients having an indolent course requiring no interventions and others who either present with or progress to metastasis. While underlying dominant driving mutations are not widespread, there have been a number of key genomic mutations that have been consistently identified in prostate cancer patients, across the disease spectrumRead More
The Impact of COVID-19 on Oncology Clinical Trials Written by ZACHARY KLAASSEN, MD, MSC AND CHRISTOPHER J.D. WALLIS, MD,PHD
May 14, 2020
The coronavirus has the potential to impact the integrity and patient safety of ongoing trials as well as increase the operational burden on trial programs, therefore potentially limiting access to trials and new therapies for oncology patients. Opportunities for clinical trial enrollment may still be provided to patients during the COVID-19 outbreak, but likely require thorough evaluation on a case-by-casebasis. Read More
Appropriate Use Criteria for Imaging Evaluation of Biochemical Recurrence of Prostate Cancer After Definitive Primary TreatmentMay 20, 2020
The purpose of this document is to describe the appropriate use of imaging in the diagnostic evaluation of patients with BCR after definitive primary treatment. The imaging modalities that were considered included CT, bone scan, and the U.S. Food and Drug Administration (FDA)–approved PET radiotracers that track malignancy-induced lipogenesis (11C-choline) and amino acid metabolism (18F-fluciclovine). Read More Risks of Delaying Bladder Cancer Diagnosis- Surveillance and SurgeryDuring COVID-19
Written by CHRISTOPHER J.D. WALLIS, MD, PHD AND ZACHARY KLAASSEN, MD,MSC
April 20, 2020
The rapid spread of Coronavirus Disease 2019 (COVID-19), caused by the betacoronavirus SARS-CoV-2, throughout the world has had dramatic effects on healthcare systems with impacts far beyond the patients actually infected with COVID-19. Patients who manifest severe forms of COVID-19 requiring respiratory support typically require this for prolonged durations,Read More
PARP Inhibitors, Prostate Cancer and a Promise Fulfilled Written by CHARLES RYAN, MDJune 30, 2020
June 26, 2020, marked the 20th anniversary of the publication of the first working draft from the Human Genome Project. At a special White House event to commemorate the results of this 10-year public effort (it was really more like 50 years since the discovery of DNA, but I digress), then-President Bill Clinton called the project “the most wondrous map ever created by humankind”, and touted its promise to detect, prevent, and treat disease. Read More Biomarker Strategies for Prostate Cancer Care During COVID-19June 24, 2020
Despite the recent disruptions in health care delivery due to the COVID-19 pandemic, patients at risk for developing prostate cancer as well as those diagnosed with prostate cancer still deserve timely and optimal decision making. Unfortunately, the uncertainty of the pandemic requires urologists to adopt innovative strategies in order to prioritize patient care while being mindful to mitigate the potential infectious risks of COVID-19 to their patients as well as to their healthcare team.Read More
PARP Inhibitors - A Breakthrough in Targeted Therapies for ProstateCancer
Written by ARPIT RAO, MBBS AND CHARLES RYAN, MDJune 29, 2020
In this review, we will summarize the current indications for PARP inhibitor monotherapies and combination(s), review data from clinical trials in prostate cancer, discuss management of commonly encountered side effects, and highlight exciting clinical research on expanding the role of PARP inhibitors in prostate cancer. Read More Germline Testing for DNA Repair Mutations in Prostate Cancer: Who,When and How?
Written by VEDA N. GIRI, MDJune 29, 2020
Understanding the role of germline testing in prostate cancer is now critical to urologic and oncology practice for metastatic castration-resistant prostate cancer. Here, we will address who should be considered for germline testing, when germline testing may influence treatment and management, and _how_ to implement germline testing involving provider practices and genetic counseling. Read More What Are the Most Common Genomic Aberrations Seen in DNA Damage Response (DDR) Pathways in Advanced Prostate Cancer? Written by PATRICK G. PILIÉ, MDJune 29, 2020
Men with advanced prostate cancer have a 10-15% risk of carrying a hereditary, or germline, variant in a DNA damage response gene. Pathogenic or deleterious variants in these same DNA damage response genes can also be found at the somatic, or tumor-associated level, in up to 25% of metastatic castrate-resistant prostate cancer. Read More PARP Inhibitors in Prostate Cancer: PROfound and Beyond Written by CHRISTOPHER J.D. WALLIS, MD, PHD AND ZACHARY KLAASSEN, MD,MSC
June 17, 2020
Prostate cancer is a clinically heterogeneous disease with many patients having an indolent course requiring no interventions and others who either present with or progress to metastasis. While underlying dominant driving mutations are not widespread, there have been a number of key genomic mutations that have been consistently identified in prostate cancer patients, across the disease spectrumRead More
The Impact of COVID-19 on Oncology Clinical Trials Written by ZACHARY KLAASSEN, MD, MSC AND CHRISTOPHER J.D. WALLIS, MD,PHD
May 14, 2020
The coronavirus has the potential to impact the integrity and patient safety of ongoing trials as well as increase the operational burden on trial programs, therefore potentially limiting access to trials and new therapies for oncology patients. Opportunities for clinical trial enrollment may still be provided to patients during the COVID-19 outbreak, but likely require thorough evaluation on a case-by-casebasis. Read More
Appropriate Use Criteria for Imaging Evaluation of Biochemical Recurrence of Prostate Cancer After Definitive Primary TreatmentMay 20, 2020
The purpose of this document is to describe the appropriate use of imaging in the diagnostic evaluation of patients with BCR after definitive primary treatment. The imaging modalities that were considered included CT, bone scan, and the U.S. Food and Drug Administration (FDA)–approved PET radiotracers that track malignancy-induced lipogenesis (11C-choline) and amino acid metabolism (18F-fluciclovine). Read More Risks of Delaying Bladder Cancer Diagnosis- Surveillance and SurgeryDuring COVID-19
Written by CHRISTOPHER J.D. WALLIS, MD, PHD AND ZACHARY KLAASSEN, MD,MSC
April 20, 2020
The rapid spread of Coronavirus Disease 2019 (COVID-19), caused by the betacoronavirus SARS-CoV-2, throughout the world has had dramatic effects on healthcare systems with impacts far beyond the patients actually infected with COVID-19. Patients who manifest severe forms of COVID-19 requiring respiratory support typically require this for prolonged durations,Read More
__
FEATURED VIDEOS
__
Radionuclide Targeted Treatment in Progressing Metastatic Prostate Cancer - Michael Hofman__ June 30, 2020
Academic and Community Practice Perspectives on Integrating PSMA Lutetium in the Clinic: Lessons Learned from Radium-223 Experience - Oliver Sartor and Nicholas Vogelzang__ June 30, 2020
PSMA-PET Imaging in Prostate Cancer & PSMA as a Therapeutic Target in Prostate Cancers - Thomas Hope and Johannas Czernin__ June 30, 2020
PSMA Targeted Radiopharmaceuticals in Prostate Cancer: Pivotal Phase III VISION Trial - Oliver Sartor__ June 30, 2020
PSMA-directed Therapy - Scott Tagawa and Michael Morris__ June 30, 2020
Radiation Safety with Targeted Radionuclide Therapy - Thomas Hope__ June 30, 2020
Precision Medicine: RadioIsotopes Targeted Therapies in Cancer -Stefano Fanti
__ June 30, 2020
Radionuclide Targeted Treatment in Progressing Metastatic Prostate Cancer - Michael Hofman__ June 30, 2020
Academic and Community Practice Perspectives on Integrating PSMA Lutetium in the Clinic: Lessons Learned from Radium-223 Experience - Oliver Sartor and Nicholas Vogelzang__ June 30, 2020
PSMA-PET Imaging in Prostate Cancer & PSMA as a Therapeutic Target in Prostate Cancers - Thomas Hope and Johannas Czernin__ June 30, 2020
PSMA Targeted Radiopharmaceuticals in Prostate Cancer: Pivotal Phase III VISION Trial - Oliver Sartor__ June 30, 2020
PSMA-directed Therapy - Scott Tagawa and Michael Morris__ June 30, 2020
Radiation Safety with Targeted Radionuclide Therapy - Thomas Hope__ June 30, 2020
Precision Medicine: RadioIsotopes Targeted Therapies in Cancer -Stefano Fanti
__ June 30, 2020
Radionuclide Targeted Treatment in Progressing Metastatic Prostate Cancer - Michael Hofman__ June 30, 2020
Academic and Community Practice Perspectives on Integrating PSMA Lutetium in the Clinic: Lessons Learned from Radium-223 Experience - Oliver Sartor and Nicholas Vogelzang__ June 30, 2020
PSMA-PET Imaging in Prostate Cancer & PSMA as a Therapeutic Target in Prostate Cancers - Thomas Hope and Johannas Czernin__ June 30, 2020
__
* About UroToday
* Editorial and Advertising Guidelines * Editors and Contributors* FAQs
* Privacy Policy
* Terms of Use
COPYRIGHT © 2002 - 2021 DIGITAL SCIENCE PRESS, INC. Follow UroToday __ ____
×
LOGIN
Login to update email address, newsletter preferences and usebookmarks.
Password
Login
* Forgot Password?
* Sign Up Free
Details
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0